Novel Antiviral Strategies Targeting the Human Immunodeficiency Virus Type 1 (HIV-1) Viral Protein R and Its Cellular Partner, the Glucocorticoid Receptor by Schafer, Elizabeth Ann
 
 
NOVEL ANTIVIRAL STRATEGIES TARGETING HUMAN  
IMMUNODEFICIENCY VIRUS TYPE 1 (HIV-1) VIRAL PROTEIN R AND 
ITS CELLULAR PARTNER, THE GLUCOCORTICOID RECEPTOR 
  
 
by 
 
 
Elizabeth Ann Schafer 
 
 
B.S., Biology, Grove City College, 2000 
 
B.A., English, Grove City College 2000 
 
 
 
 
 
 
Submitted to the Graduate Faculty of 
 
 
The Department of Infectious Diseases and Microbiology  
 
 
The Graduate School of Public Health in partial fulfillment 
 
 
of the requirements for the degree of 
 
 
Master of Science 
 
 
 
 
 
University of Pittsburgh 
 
 
2005 
  
UNIVERSITY OF PITTSBURGH 
 
GRADUATE SCHOOL OF PUBLIC HEALTH 
 
 
This thesis was presented  
 
 
by 
 
 
Elizabeth Ann Schafer 
 
 
 
It was defended on 
 
 
13 July 2005 
 
 
and approved by 
 
 
 
Velpandi Ayyavoo, Ph.D 
Thesis Advisor  
 Assistant Professor 
 Infectious Diseases and Microbiology 
Graduate School of Public Health 
University of Pittsburgh 
 
 
 Phalguni Gupta, Ph.D 
Committee Member 
Assistant Chairman and Professor  
Infectious Diseases and Microbiology 
Graduate School of Public Health 
University of Pittsburgh 
 
 
          Meryl H. Karol, Ph.D 
Committee Member 
Professor and GSPH Associate Dean  
Environmental and Occupational Health 
Graduate School of Public Health 
University of Pittsburgh 
       
 ii
 
 
 
NOVEL ANTIVIRAL STRATEGIES TARGETING HUMAN IMMUNODEFICIENCY 
VIRUS TYPE 1 (HIV-1) VIRAL PROTEIN R AND ITS CELLULAR PARTNER, THE 
GLUCOCORTICOID RECEPTOR 
 
 
 
 
 
Elizabeth Ann Schafer, MS 
 
University of Pittsburgh, 2005 
 
 
 
Most highly active anti-retroviral treatment (HAART) regimens eventually fail to provide 
complete and long-term suppression of virus replication due to the inability to fully clear virus 
from cellular reservoirs.  The HIV-1 viral protein R, Vpr, increases virus replication in T cells 
and is necessary for the optimal infection of primary monocytes/macrophages and other non-
dividing cells. In this essay, it is demonstrated that Vpr interacts with the cellular Glucocorticoid 
Receptor (GR) and transactivates the HIV-1 LTR through GRE and that this event can be 
blocked by the GR antagonist, mifepristone.  Based on these observations, it is shown that 
targeting Vpr-mediated virus transcription with the glucocorticoid antagonist, mifepristone, can 
demonstrate a potent anti-retroviral therapy.  
 
Results demonstrated that Vpr-induced transactivation of both autologous and heterologous 
promoters was inhibited by mifepristone in a dose-dependent manner by >90% at a 1 µM 
concentration.  Infectivity assays using T-tropic, dual-tropic, and macrophage-tropic viruses 
demonstrated antiviral effects on a dose-dependent regimen of mifepristone.  The effects of 
 iii
mifepristone were also tested in HIV-1 latent cells that could be activated with extra-cellular 
viral protein and results exhibited a greater than 90% inhibition of re-activation in the presence 
of this antagonist. Cytotoxic effects of mifepristone demonstrated a CT50 from 10 to 100 µM in 
normal human primary cells, HeLa, HEK293, and CV-1 cells.   
 
Statement of Public Health Relevance:  By utilizing the interaction between Vpr and the 
glucocorticoid receptor, glucocorticoid antagonists such as mifepristone hold promise for anti-
retroviral therapy by both preventing viral transactivation in currently-infected cell populations 
as well as preventing the reactivation of latent virus.     
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 1. CHAPTER ONE: INTRODUCTION 
 
1.1. AIDS:  The Epidemic 
 
There are currently an estimated 42 million people infected world-wide with HIV/AIDS (Human 
Immunodeficiency Syndrome/Acquired Immune Deficiency Syndrome), with approximately 
14,000 new infections occurring every day (1) (Table 1).  While current therapies including 
highly active anti-retroviral drug therapy (HAART) have without doubt prolonged the lives of 
many fighting HIV and have prevented innumerable new infections, the drug regimen is costly 
and adherence is generally low due to both toxicity and drug failure (2,3). Studies have shown 
that a regimen adherence of 95-98% is necessary to control infection and that missing even a 
single dose in a 28-day period can predict treatment failure (4,5). The evolution of drug-resistant 
viral strains has been shown to occur due to the non-adherence of therapy in a “bell-shaped 
manner”: medium regimen adherence increases drug resistance in comparison to low or high 
adherence (6,7).   
 
Four major classes of antiviral therapy are currently prescribed, which include the new fusion 
inhibitors, protease inhibitors, and reverse transcriptase inhibitors. Generally, HAART is 
administered as “triple therapy” consisting of a protease inhibitor (PI) or a non-nucleoside 
reverse transcriptase inhibitor (NNRTI) as well as two nucleoside reverse transcriptase inhibitors 
(NRTI) (8).  Unfortunately, these therapies often lead to toxic side effects including 
mitochondrial toxicity, lipodystropy, lactic acidosis, hepatatoxicity, and cardiomyopathy (9-12). 
Currently, other antiviral targets are being explored including integrase inhibitors, CXCR4 and 
1 
 CCR5 inhibitors, and cellular proteins including APOBEC3G and TRIM5α that demonstrate 
antiviral behavior (13-18). 
 
Viral reservoirs such as macrophages and resting T cells prevent total viral clearance even during 
an extensive HAART regimen (19-22). Though there is some speculation that patients treated 
with HAART <6 months post-seroconversion are able to decrease latent viral loads to less than 
detectable levels, it is hypothesized that patients would have to undergo 60 years of HAART to 
clear all viral reservoirs (23,24). While there is great pursuit to find new therapies or vaccines, 
there is a substantial need to find additional novel compounds which will target areas of virus 
replication not yet investigated for antiviral intervention.    
 
 
 
 
 
 
 
 
 
 
 
 
 2.9 Million1.1%4.8 Million37.8 MillionTotal
44,0000.1200,000900,000East Asia
7000.25,00032,000Oceania
15,0000.644,0001 MillionNorth America
6,0000.320,000580,000Western Europe
49,0000.6360,0001.3 MillionEastern Europe and 
Central As ia
35,0002.352,000430,000Caribbean
84,0000.6200,0001.6 MillionLatin America
460,0000.6850,0006.5 MillionSouth and South-
East Asia
24,0000.275,000480000North Africa and 
Middle East
2.2 Million7.53 Million25 MillionSub-Saharan Africa
Adult and Child Deaths 
due to AIDS
Adult P revalence Rate 
(%)
Adults and Children 
Newly Infected with 
HIV
Adults and Children 
Living with HIV
World Region
Table 1. Regional HIV and AIDS statistics (2003).  There are currently an estimated 42 million people infected 
with HIV/AIDS around the world. UNAIDS and WHO statistics show the largest number of HIV/AIDS cases 
occurring in Sub-Saharan Africa and South or South-East Asia.    
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 2. CHAPTER TWO:  BACKGROUND 
 
2.1. HIV-1:  STRUCTURE, REPLICATION, PATHOGENESIS 
 
The human immunodeficiency virus type 1 (HIV-1), the etiologic agent of AIDS, is classified as 
a member of the Retroviridae family; more specifically, as a member of the Lentiviral genus.  
The 9.8 kilobase single-stranded HIV-1 genome is composed of at least nine genes coding for  
structural/enzymatic (gag, env, pol), regulatory (tat, rev) and accessory (vif, vpr, nef, vpu) 
proteins (Figure 1, Table 2).  
 
Figure 1. The HIV-1 Genome.  The schematic representation of the HIV-1 genome includes both structural 
and accessory genes including gag, pol, vif, tat, vpr, rev, vpu, env, and nef.  These genes are flanked on both 
ends by the HIV-1 LTR (long terminal repeat) promoter region. 
LTR LTR
GAG
POL
VIF  TAT VPU                    TAT          NEF
VPR    REV                       REV
ENV
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 Table 2. Functions of HIV-1 Proteins.  The nine proteins composing HIV-1 are listed along with their 
respective functions. 
 
V i ra l P ro te i n  R ;  t ra ns p o r t  P I C ,  a p o p to s is ,  t ra n s a c t iv a t i o n ,  G 2  c e l l  
c y c le  a r re s t
V p r
g p 4 1  a n d g p1 2 0 ;  c o m p r is e s  th e  v ir a l  e n v e lo p e ;  a tt a c h m e n tE n v
D o w n - m o d u l a t io n  o f  C D 4 ;  E n h a n c e s  v i r io n re le a s eV p u
T ra n s c r i p t io n a l  A c t iv a to r ;  E n ha n c e s  g e n e  tr a n s c r i p t i o nT a t
R e g u la t o r  o f  E x p re s s i o n;  P r o m o t e s  n u c le a r  e x p o r t  o f  R N AR e v
P re c u r s o r  to  P ro te a s e  (P R ) , I n t e g ra s e (I N ) , a n d  R e v e rs e  
T ra n s c r i p t a s e  (R T )
P o l
M a tr i x ( M A ),  C a p s id (C A ) , N u c le o c a p s i d (N C )  s t r u c t u ra l  
p ro te i n s ;  p 2 4 ;  p 6  ( i n t e ra c t s  w i th  V p r i n  t h e  c a p s i d )
G a g
N e g a t i v e  F a c t o r ;  D o w n re g u la te s C D 4  a n d  M H C I  e x p re s s io n , R o le  
i n  v i ra l pa th o g e n e s i s
N e f
V i ra l I n fe c t iv i ty  F a c to r ;  R T  c o m p le x  s ta b il i ty ,  d e g ra d e s  
A P O B E C 3 G
V if
F u n c t io nH I V - 1  P ro te i n
 
The long terminal repeat (LTR) flanks both ends of the viral genome, and serves as the major 
promoter region for viral transcription (Figure 2).  The HIV-1 LTR contains multiple binding 
sites for transcription factors including the glucocorticoid receptor, SP-1, NF-AT, and NF-ĸB. 
 
Figure 2.  HIV-1 Long Terminal Repeat (LTR).  The LTR is the main promoter region for HIV-1 viral genes.  
The main transcription factor binding sites are found in the U3 region of the LTR and are schematically 
represented. 
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 Briefly, upon entry into host cells, HIV-1 RNA is reverse transcribed into DNA in the cytoplasm 
of the cell, resulting in the entry of viral DNA into the nucleus of the cell and leading to 
subsequent integration with host DNA (Figure 3). Target cells of HIV-1 infection include both 
the dividing CD4+ T cells and non-dividing macrophages (25-27). Post-infection, latent 
reservoirs are established in various cell types including both T cells and macrophages and serve 
as the cause for both initial asymptomatic infection as well as the inability to fully expel virus 
from infected patients (28). 
 
 
NUCLEUS 
Attachment 
Fusion 
Uncoating RT
Integration 
HIV-1 
Protein 
Expression 
Assembly 
Egress
CYTOPLASM 
 
Figure 3. Replication of HIV-1 Genome.  HIV-1 attaches and fuses through the cellular membrane.  The RNA 
uncoats in the cytoplasm and reverse transcription (RT) occurs.  Viral DNA integrates with cellular DNA, 
leading to the production of viral proteins which in conjunction with viral RNA, assemble at the cellular 
membrane where the virus fully assembles, matures, and egresses into the extra-cellular environment. 
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 2.2. THE ACCESSORY PROTEIN, VPR 
 
As aforementioned, HIV-1 is composed of at least four accessory proteins. One of these 
accessory proteins and the one in which the focus of this thesis concerns, viral protein R (Vpr), is 
96-amino acids in length with a molecular weight of approximately 14 kDa.  Vpr can be defined 
as a pleiotropic protein, as it has been shown to serve in an array of varying functions including 
cell cycle arrest at the G2/M phase, immune regulation and evasion, apoptosis, involvement with 
the pre-integration complex (PIC), and viral transactivation (29-39).  It is this final function, viral 
transactivation, which will be further investigated throughout this essay.      
 
While defined as an accessory protein, Vpr is evolutionarily conserved in HIV-1, HIV-2, and 
SIV, demonstrating its importance as a viral protein (40). Vpr is also packaged within the virion, 
possibly transactivating viral genes prior to the production of Tat (41). Studies have shown that 
Vpr, while important during infection of dividing cells such as T cells, is vital to the infection of 
non-dividing cells such as macrophages, possibly due to its involvement with PIC (42-44).  
Important to note is that macrophages are the primary initial targets of HIV-1, specifically 
located within the mucosa of the skin (45).  The importance of Vpr in the initial stages of 
infection, therefore, can be demonstrated by the necessity of Vpr for optimal macrophage 
infection during initial virus/host cell contact.        
 
Vpr is composed of three helices (Helix I, II, and III) connected by loop regions (Figure 4) (46).  
Each helix contains the motif LxxLL, which has been shown to interact with cellular proteins 
(47,48). These LxxLL motifs are involved in the interaction of Vpr with the cellular protein, the 
6 
 glucocorticoid receptor (GR) (49).  Thus the specific interaction between Vpr and GR, which 
increases transactivation of viral proteins, is a probable target for antiviral intervention. 
 
 
LXLLXXL20
26
LXXL39 42 LXXLL
64 68
I II III
N C
A 
B 
Figure 4. (A) Schematic Representation of Vpr. (B) Schematic Representation of Helices I, II, and III.   
 
2.3. THE GLUCOCORTICOID RECEPTOR AND ITS ROLE IN VPR-MEDIATED 
VIRAL TRANSACTIVATION 
 
The Glucocorticoid Receptor (GR) is a host cellular ligand-dependent transcription factor and a 
member of the nuclear hormone receptor family.  Under normal conditions, GR serves mainly as 
a negative regulator of NF-κB- and AP-1-induced gene transcription (cytokine production) 
(50,51). 
7 
 GR
 
Figure 5.  The GR Pathway.  The Glucocorticoid Receptor is held in the cytoplasm by heat shock proteins and 
other chaperones.  Cortisol binds the GR within the Ligand-Binding Domain and activates GR.  A 
conformational change after ligand binding dislodges the chaperones and presents nuclear localization 
signals.  GR then translocates into the nucleus where it bind the Glucocorticoid Response Element (GRE) 
promoter region within the cellular DNA, leading to the transactivation of downstream genes.  GR is also able 
to bind to negative GRE elements, regulating NF-ĸB-driven gene expression. 
 
GR is held in the cytoplasm of the cell by a heteromeric complex composed of several proteins 
including HSP90, HSP70, P23, and other chaperone proteins (52-55).  Once ligand binds the GR 
within its ligand-binding domain region (LBD), GR is released from this complex and 
translocates into the nucleus of the cell where it binds specific promoter response elements 
termed Glucocorticoid Response Elements, or GREs (56,57) (Figure 5).  One of the ways in  
which GR is able to negatively regulate the effects of the pro-inflammatory response is by 
binding to negative GREs or nGREs, which decreases gene transcription (58).  GR also interacts 
with other transcription factors through direct protein-protein interaction, inhibiting gene 
GR
GRE
Nucleus
Cytoplasm
HSP90
Cortis ol
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 transactivation, as well as enhancing transactivation of anti-inflammatory cytokines, thereby 
combating the effects of cytokine-enhancing transcription factors such as NF-κB (59,60)  
 
The Glucocorticoid Receptor contains three specific domains:  AF-1 domain, DNA-binding 
domain, and the Ligand-binding domain (Figure 6) (61). The N-terminus AF-1 domain, 
consisting of amino acids 1-421, is a transcriptional activation function domain (62).  The GR 
DNA-binding domain (DBD) is comprised of the next 65 amino acids and contains a zinc-finger 
DNA-binding motif which interacts with GREs (63).  The C-terminus Ligand-binding domain 
(LBD) is made of 250 amino acids and both interacts with ligand as well as is involved in 
protein-protein interaction with chaperones and co-regulators (64).  GR consists of at least two 
nuclear localization signals found in both the DBD and LBD regions (65). 
1   77   262                 407         545   573                                              777
 
Figure 6. Schematic Representation of the Glucocorticoid Receptor.  The Glucocorticoid Receptor is made of 
the N-terminus AF-1 domain, the DNA binding domain, and the C-terminus Ligand binding domain. 
 
Vpr is able to directly interact with GR and act as ligand, increasing the transactivation of GRE-
driven downstream genes.  While it is currently unknown where Vpr binds GR, we have shown 
that the Vpr and GR interaction is mediated through the LxxLL motifs present in Vpr helices II 
and III (49). 
 
LBDDBD LBD  AF-2t2AF-1
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2.4. THE GR ANTAGONIST, MIFEPRISTONE 
 
Mifepristone, (11β-[p-(Dimethylamino)phenyl]-17β-hydroxy-17-(1-propynyl)estra-4,9-dien-3-
one),  empirical formula C29H35NO2, and a derivative of norethindrone, is a yellow powder with 
a molecular weight of 429.6 and a melting point of 191-196oC (Figure 7).  It is soluble in 
methanol, chloroform, and acetone (66).  
 
{H3C}2N
Figure 7.  Structure of mifepristone. 
 
Mifepristone was originally synthesized by scientists at Roussel-Uclaf in Romainville, France 
while searching for steroidal compounds with anti-hormone properties (67-69). Defined as a 
class II GR antagonist, mifepristone demonstrates strong antagonistic effects on GR and the 
Progesterone Receptor (PR) with some sited instances of agonist activity towards GR, dependent  
upon receptor concentration (70,71).  Mifepristone, which binds at the GR ligand-binding 
domain in the same pocket as dexamethasone, is able to exert antagonistic effects on GR-
mediated transactivation by both tightening the bind between GR and GRE, thereby decreasing  
H CH3
OH
C   CCH3
H
H
O
Mifepristone
10 
 the rate of speed in which gene transcription occurs (72,73), and by recruiting co-repressors 
rather than co-activators to the transcription complex, thus decreasing transactivation (74).  It is 
this interaction between mifepristone and GR that produces a possible target for antiviral 
therapy. 
 
2.5. THE PROPOSED RELATIONSHIP BETWEEN VPR, GR, AND MIFEPRISTONE 
 
 
We have shown that Vpr and GR specifically interact, and that Vpr is able to act as ligand in a 
similar manner to that of dexamethasone, increasing GR-mediated transactivation (49). Looking 
more specifically at viral transcription, found within the HIV-1 LTR promoter region are GRE 
sequences (75).  Therefore, during infection, GR-mediated transactivation of GRE-promoted 
downstream gene does not only occur in the context of cellular DNA, but can also occur with the 
integrated HIV-1 proviral DNA, thereby increasing viral transcription (viral production).  We 
therefore propose that Vpr, either nascently transcribed within the host cell, or Vpr which has 
transduced through the cellular membrane (free Vpr), is able to bind GR similar to ligand, 
leading to the binding of GR to the GRE promoter region found within the HIV-1 LTR, thereby 
promoting the transactivation of viral genes.  And that the GR antagonist, mifepristone, is able to 
therefore decrease or inhibit Vpr/GR-mediated viral gene transactivation in infected cells (Figure 
8).  The decrease or prevention of Vpr-mediated transactivation of viral genes also allows for the 
opportunity to inhibit or decrease reactivation from viral reservoirs, as the integrated proviral 
DNA will be less likely to transactivate (reactivate) in the presence of the GR antagonist, 
mifepristone.  This is especially important in the context of macrophages in which Vpr is 
necessary to infect, and in which viral reservoirs are often present.  
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Figure 8. Schematic Representation of Vpr-mediated LTR transactivation.  Vpr interacts with GR as ligand, 
similar to cortisol, leading to the transactivation of GRE-driven genes, including those found in the HIV-1 
LTR. Mifepristone is able to decrease this transactivation via several different mechanisms.   
  
 
 
2.6. CURRENT ANTI-RETROVIRAL THERAPY 
 
Currently, there are four classes of anti-viral therapy targeting different steps in HIV-1 
replication within the host cell (Table 3, Figure 9).  Briefly, these therapies target either reverse 
transcription (AZT, efavirenz, 3TC), protease maturity (indinavir, ritonavir), or fusion (Fuzeon).  
Other classes of drugs are being investigated and offer hope for HIV-1 infected patients, as drug-
resistant viral strains are becoming more and more frequent within infected populations, and as 
the adverse effects to the drugs themselves often cause patients to fail therapy.  
GR
GR
LTR
Nucleus
Cytoplasm
HSP90
Vpr
LTR
Mifepristone
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Table 3.  Four Classes of Retroviral Therapy and Associated Drugs.  The current HIV-1 antiviral drugs which 
are FDA-approved are listed as follows along with their common names and abbreviations. 
 
Common Name Abbreviation Drug 
Nucleoside and 
Nucleotide RT 
Inhibitors 
(NRTIs)Trade name 
    
Combivir CBV AZT+3TC 
Emtriva FTC Emtricitabine 
Epivir 3TC 3TC, lamivudine 
Hivid ddC ddC, zalcitabine 
Kivexa   3TC+ABC 
Retrovir AZT AZT, zidovudine 
Trizivir TZV AZT+3TC+ABC 
Truvada   FTC+TDF 
Videx ddI ddI, didanosine 
Viread TDF Tenofovir 
Zerit d4T d4T, stavudine 
Ziagen ABC Abacavir 
Non-Nucleoside RT 
Inhibitors (NNRTIs) 
    
Rescriptor DLV Delavirdine 
Sustiva EFV Efavirenz 
Viramune NVP Nevirapine 
Protease Inhibitors 
(PIs) 
    
Agenerase APV Amprenavir 
Crixivan IDV Indinavir 
Fortovase SQV-FTV Saquinavir soft gel 
Invirase SQV-INV Saquinavir hard gel 
Kaletra LPV Lopinavir/ritonavir 
Lexiva/Telzir FPV Fosamprenavir 
Norvir RTV Ritonavir 
Reyataz ATV Atazanavir 
Viracept NFV Nelfinavir 
Fusion inhibitors     
Fuzeon T-20 Enfuvirtide 
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Fusion Inhibitors
 
 
Figure 9. Targets for Antiviral Therapy within the HIV-1 Life Cycle. Current antiviral therapy (Fusion 
Inhibitors, RT Inhibitors, and Protease Inhibitors) in conjunction with possible antivirals (Integrase 
Inhibitors, CXCR4 and CCR5 Inhibitors, Cellular Inhibitors, and Transactivation Inhibitors) are 
schematically represented. 
 
2.7. PUBLIC HEALTH SIGNIFICANCE 
 
With an estimated 42 million people infected with HIV/AIDS around the world, there is great 
need for new therapies targeting HIV-1 infection that are both inexpensive as well as easily 
accessible.   While current HAART therapy has increased the lifespan of thousands of people 
and prevented many new infections by both vertical and horizontal transmission, the inability of 
many infected patients to correctly follow the drug regimen along with the development of viral 
reservoirs and drug-resistant strains, results in the need for the presentation of new antivirals, 
 
NUCLEUS
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Fusion 
UncoatingRT
Integration
HIV-1 
Protein 
Expression 
Assembly
Egress
CYTOPLASM 
CXCR4 and CCR5
Inhibitors
RT Inhibitors
Integrase Inhibitors
Protease Inhibitors
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 targeting different stages of the viral lifecycle.  Recently, accessory proteins such as Vif and Nef 
have been investigated to determine if these proteins hold any answers for finding new antiviral 
drugs.  Along that line, the interruption of Vpr-mediated transactivation via mifepristone could 
give rise to a new class of antiviral drugs, one which could target both active replication as well 
as viral reservoirs.  Conceding that this therapy would not be the end-all-be-all of therapies, we 
propose that it could, in fact, be incorporated into current HAART therapy as a combative 
antiviral. 
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3. CHAPTER THREE: THESIS AIMS 
 
With the development of HAART, HIV-1-infected patients have been able to prolong their lives 
as well as help prevent the spread of virus to others.  However, HAART therapy almost always 
eventually fails leading ultimately to the death of the patient due to complications of 
opportunistic infection.  Viral reservoirs are often established within the patients and viral-
resistant species develop within those infected, leading to a down-hill battle concerning 
overcoming the fight with HIV-1.   
 
The necessity of developing new antiviral compounds to combat HIV-1 infection has led to the 
investigation of specific proteins encoded by the virus, including the accessory protein Vpr.  Vpr 
has been implicated in a variety of functions including G2M cell cycle arrest, apoptosis, immune 
regulation, viral escape, and finally, an increase in viral transactivation.  It has been determined 
that one of the mechanisms underlying Vpr-mediated transactivation is through the utilization of 
the pathway established by the Glucocorticoid Receptor (GR).  Vpr is able to activate GR in a 
ligand-dependent manner, similar to that of cortisol, leading to the transactivation of GRE-driven 
genes.  The HIV-1 LTR, which contains GRE sequences, promotes the transcription of viral 
genes in the presence of Vpr, mediated by the interaction between Vpr and GR.   The GR 
antagonist, mifepristone, is able to inhibit Vpr-mediated transactivation by interfering on several 
levels with the transcription of GRE-promoted genes.   
 
The three major aims of this thesis included first defining the relationship between Vpr and GR 
and the subsequent increase in viral transactivation.   Secondly, we wanted to assess whether or 
16 
 not the GR antagonist, mifepristone, was able to inhibit viral gene transactivation and viral 
replication in both transactivation models and infectivity models.  Third, we wanted to view the 
effects of  mifepristone in a clinical manner, to determine if mifepristone worked differently in a 
pre- versus post-treatment regimen and to investigate the effects of mifepristone on reactivation 
from latency.  Mifepristone analogs were also investigated to assess their ability to inhibit HIV-1 
LTR-mediated transactivation as well as viral replication. 
 
AIM #1:  To determine the relationship between Vpr and GR and their role in virus  
      replication   
 
   
A)  To test the effects of Vpr on LTR-mediated transactivation 
  B)  Determine how Vpr increases LTR-mediated transactivation 
  C)  Determine the specific interaction between Vpr and GR resulting 
        in downstream transactivation   
 
AIM #2:   To assess whether the GR antagonist, mifepristone, is able to inhibit viral  
       transactivation and virus replication  
 
  A)  Determine the cytotoxicity of mifepristone 
  B)  Study effects of mifepristone on transactivation models 
  C)  Assess effects of mifepristone in T-tropic, dual-tropic, and M-tropic infection 
        models 
  D)  Determine effects of mifepristone patient isolate infection models 
 
AIM #3:  Clinical Applications of Mifepristone 
 
A)  Determine if mifepristone works differently in a Pre vs. Post Antiviral   
       Infection Study              
B)  Determine if mifepristone is able to prevent reactivation of virus from  
        latency 
  C)  Study the effects of mifepristone analogs on viral transactivation and infection 
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4. CHAPTER FOUR: MATERIALS AND METHODS 
 
4.1. Cell Lines 
4.1.1. Established Cell Lines 
HeLa, HEK293, HEK293T, and TZM cell lines were grown in DMEM (Gibco, Carlsbad, 
California) supplemented with 10% FBS (HyClone, Logan, Utah), 1% Penicillin-Streptomycin, 
and 1% L-Glutamine.  Both HeLa and TZM cells were grown in 5% CO2 at 37˚ C; HEK293 and 
HEK293T cell lines were grown in 10% CO2 at 37˚ C.  CV-1 cells were sustained in DMEM 
supplemented with 10% charcoal/dextran-stripped FBS (HyClone, Logan, Utah) at 5% CO2 at 
37˚ C.  HeLa cells were obtained from the NIH AIDS Research and Reference Reagent program 
from Dr. Richard Axel (76).  CV-1 cells were obtained from Dr. Frank Jenkins at the University 
of Pittsburgh and TZM-bl cells were received from the AIDS Research and Reference Reagent 
program from Drs. John C Knappes, Xiaoyun Wu, and Tranzyme, Inc.  HEK293T cells were a 
generous gift from Dr. Michelle Calos, Stanford University, CA.  HEK293 cells were from NIH 
AIDS Research and Reference Reagent Program.  U1/HIV-1 and CEM cell lines were grown in 
RPMI 1640 (Gibco, Carlsbad, California) and supplemented with 10% FBS, 1% L-Glutamine, 
and 1% Penicillin-Streptomycin as.  174xCEM cells were provided by Dr. Peter Cresswell (77) 
and were received from the AIDS Research and Reference Reagent Program.  The U1/HIV-1 
cell line was acquired through the AIDS Research and Reference Reagent Program as 
contributed by Dr. Thomas Folks (78).   
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4.1.2. Primary Cells 
PBMCs:  Peripheral Blood Mononuclear Cells (PBMCs) were isolated using blood from healthy 
male HIV-1-negative donors.  Male donors were used to avoid the irregulation of hormone 
cycling in women.  Blood was isolated using Lymphocyte Separation Media (Mediatech, 
Herndon, Virginia) gradient centrifugation.  Post-isolation, PBMCs were resuspended in RPMI 
1640 supplemented with 10% FBS and stimulated with phytohemoagglutinin (PHA-P) (Sigma, 
St. Louis, Missouri) (5µg/mL) for three days.  After stimulation, cells were cultured in RPMI 
supplemented with 10% FBS in the presence of IL-2 (Chiron, Emoryville, California)   (5U/mL). 
 
Human Monocyte-Derived Macrophages:  Monocyte-derived macrophages were isolated from 
PBMCs by adhesion.  PBMCs were resuspended in DMEM supplemented with 1% Penicillin-
Streptomycin and 1% L-Glutamine without the presence of serum and were plated in either 
100mM plates (20 x 106), 6-well plates (3 x 106/well), 12-well plates (1.5 x 106/well), or 96-well 
plates (1.5 x 105/well) for two hours at 37˚ C, to allow the monocytes to settle and adhere to the 
plates.  After the two-hour incubation, non-adherent cells (primary blood lymphocytes) were 
excluded by removing the cells and the adherent cells were washed two times in phosphate 
buffered saline (PBS) to remove all particulates including fat, debris, and other cells attached to 
the monocytes.  DMEM supplemented with 10% FBS, 10% either horse or human sera, 1% 
Penicillin-Streptomycin, 1% L-Glutamine, 500 U/mL GM-CSF (granulocyte-macrophage colony 
stimulating factor) (Berlex Labs, Richmond, California), and 15ng/mL M-CSF (macrophage 
colony stimulating factor) (Amgen, Thousand Oaks, California) were added to the cells to begin 
the differentiation of the monocytes into macrophages.  After five days, the monocyte media was 
19 
 removed and spun down to remove any floating cells (not of monocyte lineage) and other debris.  
Half of this media was placed back on the cells and an equal quantity of fresh monocyte media 
was placed on the cells to ensure the proper cytokines and nutrients were administered to the 
cells.  After eight to ten days, macrophages were differentiated as determined by visual 
assessment (Figure 10) and CD14 FACS analysis.   
 
Figure 10.  Fully Differentiated Macrophages.  Human monocytes were isolated as described and 
differentiated into macrophages in the presence of GM-CSF and M-CSF for approximately 8-10 days.  When 
macrophages were fully differentiated, which was determined by both CD14 and visual assessment 
(“pancake” morphology), they were able to be infected with virus.   
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 4.2. Plasmids 
 
For transactivation studies, the HIV-1 LTR reporter construct was obtained from NIH AIDS 
Research and Reference Reagent Program.  The GRE (5X)-Luciferase reporter plasmid was 
constructed by PCR amplification of the 5X GRE consensus sequence from pGRE5/EBV vector 
(USB, CA) using specific forward (5’ ATACGCGGATCCTCTAGA AGATCCGCT3’) and 
reverse (5’ ATCATACTCGAGGGCCCTCGCAGACA3’) primers.  Amplified PCR product 
(290bp) was cloned upstream of a firefly luciferase gene reporter construct.  The human 
Glucocorticoid Receptor-alpha gene (hGRα) was PCR amplified using specific forward (5’ 
ATCGGGGATCCGATGGACTCCAAAGAATCA3’) and reverse (5’ 
GTGGTCCTCGAGCTTGATGAAACAGAAG 3’) primers and cloned into the pcDNA 3.1 
(Invitrogen) vector for futher expression studies.  Mutants of HIV-1 Vpr were generated using 
overlap PCR and/or by Quick-change mutagenesis (79) and were cloned under the control of the 
CMV promoter in pCDNA3.1 (Invitrogen, California) with a flag epitope.  All plasmids were 
generated by propagation in DH5α bacterial cells and DNA was extracted by using either DNA-
binding columns (Qiagen, Valencia, California)  The integrity of the plasmid DNA was tested by 
both digest and electrophoresis followed by DNA sequence analysis (ABI 7700, CA). 
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 4.3. Transfection Methods 
 
4.3.1. Calcium Phosphate 
 
The calcium phosphate method was used on HEK293 and HEK293T cell lines.  Cells were 
plated to reach an approximate confluency of 75%.  Three to four hours prior to cell transfection, 
old media was removed and 9mL fresh DMEM supplemented with 10% FBS was added to a 
100mM plate; plates were moved from 10% CO2 to 5% CO2.  The transfection was conducted 
adding DNA (450µL) to water (450µL) to 2.5M CaCl2  (50µL).  To the DNA-water-CaCl2 mix, 
50 mM BES (BES,  250mM NaCl, 0.5mM Na2HPO4) (500µL) was added and the mixture was 
incubated at room temperature for 30 minutes.  After incubation, the mixture was added drop-
wise to the surface of the cell media.   Within 12-16 hours, the media on the cells was removed, 
the cells were washed two times with PBS to remove all precipitate and excess DNA, and fresh 
DMEM supplemented with 10% FBS, 1% Penicillin-Streptomycin, and 1% L-Glutamine was 
added.  For transfections conducted in a smaller plate, all volumes were proportioned so that 
volume ratios were equivalent.     
 
4.3.2. Lipid-Mediated Transfection 
 
Lipid-mediated transfection was used on HeLa and CV-1 cells.  Cells were plated and grown in 
penicillin-streptomycin-free media overnight to 85% confluency.  DNA was mixed with 
Lipofectamine (3µL per approximately 3-5µg DNA) (Invitrogen, Carlsbad, California) and either 
OptiMEM (GIBCO, Carlsbad, California ) or DMEM was mixed to a total volume of 200µL.  
The DNA-Lipofectamine complex was incubated at room temperature for 20 minutes.  Post-
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 incubation, cell media was removed and cells were washed two times to remove any serum.  The 
DNA-Lipofectamine complex was added drop-wise to the cell surface and OptiMEM or DMEM 
without penicillin-streptomycin was added to a volume just covering the cell monolayer.  The 
cells were incubated at 37˚C for 3-4 hours.  After incubation, the DNA-Lipofectamine-
containing media was removed, cells were washed to remove any excess DNA or Lipofectamine, 
and fresh media was added.   
4.4. Virus 
 
HIV-1 89.6 was received from the NIH AIDS Research and Reference Reagent Program from 
contributor Dr. Ronald Collman (80) and propagated in PBMCs for two weeks with the addition 
of feeder PBMCs after seven days of infection. 89.6 is a dual-tropic virus specific for R5- and 
X4-expressing cells. HIV-1 Ba-L was received from the NIH AIDS Research and Reference 
Program, contributed by Drs. Suzanne Gartner, Mikulas Popovic, and Robert Gallo (81), and was 
propagated in PBMCs for two weeks, with the addition of feeder PBMCs after seven days.  Ba-L 
utilizes the R5 receptor. The patient isolate, H112, was from the NIH AIDS Research and 
Reference Reagent Program.  pNL4-3wt was contributed by NIH AIDS Research and Reference 
Reagent Program.  pNL4-3-EGFP was a kind gift from Dr. David Levy (University of Alabama) 
and was constructed as described (82).  For all viruses, viral titer was determined through p24 
ELISA and number of infectious particles were determined by TZM assay. 
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 4.5. Mifepristone and Analogs 
 
Mifepristone was purchased from Sigma, St. Louis, Missouri. Mifepristone analogs were a 
generous gift from the National Cancer Institute from Dr. Robert Schultz.   Analogs were 
dissolved in DMSO.   The compound mifepristone will not dissolve in water, and is dissolved in 
methanol.  Initial studies involved a comparison between dissolving mifepristone with both 
methanol and ethanol in both transactivation studies as well as antiviral studies. Results 
demonstrated no significant difference in the effects of mifepristone on either transactivation or 
antiviral assays, therefore ethanol was used to dissolve mifepristone for all subsequent assays.  In 
order to assess the effects of ethanol on transactivation and antiviral studies, ethanol controls 
were used.  With the exception of U1 latent reservoir studies, ethanol demonstrated no 
significant effect in any assay conducted. 
 
4.6. TZM Assay 
 
The TZM cell line is an R5 and X4 indicator cell line that enables the analysis of HIV-1-infected 
cells containing both the luciferase and β-gal reporter genes.  Receptor-mediated viral entry 
results in the transactivation of the luciferase and β-gal reporter genes which are downstream of 
the LTR promoter region.  TZM cells were plated in a 96-well plate (15,000 cells/well) overnight 
to allow adherence. After adherence, virus was added to the cells in triplicate in serial dilutions. 
Cells and virus were incubated for eight hours in 37˚C to duplicate the normal amount of time 
cells were infected in subsequent assays.  After incubation, the virus-containing media was 
removed and cells are washed two times in PBS to remove all excess virus and fresh media were 
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 then added to the cells. In order to determine the actual number of infectious particles prior to 
virus replication, twenty-four hours post-viral addition, cells were fixed in 0.5% Gluteraldehyde 
for 15 minutes and washed two times in PBS after fixation.  In order to determine the number of 
infectious particles as determined by β-gal, an X-gal reaction mix (40mg/mL MgCl2, 0.5M X-
gal, K Ferrous Cyanide, K Ferric Cyanide) as added to the cells for thirty minutes at 37˚ C.  After 
color had developed, cells were washed once in PBS and PBS was then added to the cells to 
allow for counting.  Cells were counted per well and the number of infectious particles/mL were 
calculated. 
4.7. Cytotoxicity Assay 
 
To determine the percent of cytotoxicity in vitro of cells in the presence of mifepristone and 
analogs, the MTT Tetrazolium Assay, developed by T. Mosmann (83) was performed as follows:   
 
Adherent cells: HeLa, HEK293, or CV-1 cells were plated (15,000/well) in a 96-well plate 
overnight for adherence.  Mifepristone and analogs were then administered in triplicate in serial 
dilutions of differing concentrations for three days in a total volume of 200µL.  After the three-
day incubation, MTT (3-(4,5,dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) dye 
solution (5mg/mL in phosphate buffer pH 7.4) (Sigma, St. Louis, Missouri) was added 
(20µL/well) for 4-5 hours at 37˚C in 5% CO2.  After incubation with the MTT dye solution, cell 
media was removed and 200µL of DMSO was added by flushing so that the MTT salt crystals 
would fully dissolve.  The cells were placed back in 37˚C for five minutes and read on a 
colormetric plate reader at 490nm. 
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 Macrophages:  After isolation, PBMCs were plated on a 96-well plate (150,000/well) for two 
hours while monocytes adhered to the plate.  After two hours, non-adherent cells (PBLs) were 
removed and macrophage media (containing GM-CSF and M-CSF) was added to the cells.  After 
five days, half the media was removed and fresh macrophage media was added.  Once full 
differentiation of monocytes to macrophages had occurred (approximately 8-10 days), 
mifepristone and analogs were added in triplicate in serial dilutions in varying concentrations for 
three days.  After the three-day incubation with the compounds, 20µL MTT dye solution was 
added to the media.  The solution was incubated with the cells at 37˚C in 5% CO2 for 4-5 hours.  
Cell media was then removed and DMSO was flushed to dissolve MTT crystals.  Cells were 
incubated an additional 5 minutes at 37˚C to fully dissolve all crystals and results were 
determined by reading optical density on a colormetric plate reader at 490nm.  For the seven-day 
timepoint, mifepristone was administered at day one and at day four .  After seven days, the 
MTT assay was performed as described and percent viability was calculated based on O.D. 
 
PBMCs:  After PHA-P stimulation, PBMCs were resuspended in IL-2-containing media and 
plated (15,000 cells/well) in a 96-well plate.  Mifepristone and analogs were added in triplicate 
in serial dilutions to the cells in varying concentrations for three days.  After three days, MTT 
dye solution was added (20µL) and incubated at 37˚C for 4-5 hours.  Cells were then spun down 
at 1000 rpm for 5 minutes and media was removed.  DMSO (200µL) was added to the cells by 
flushing to dissolve all MTT crystals.  Cells were incubated an additional 5 minutes at 37˚C to 
further dissolve salt crystals and results were determined by reading on a colormetric plate reader 
at 490nm.   In order to determine percent viability at a seven-day timepoint, infected cells were 
counted by trypan blue exclusion and results presented as percent viability. 
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Calculations:  To determine percent cytotoxicity, the O.D. results from the samples were 
divided by the O.D. from the positive control (cells without the presence of compound) and 
multiplied by 100.   
 
4.8. Luciferase Reporter Assay 
 
Dose Parameters: HeLa, CV-1, and HEK293 cells were co-transfected with the HIV-1 LTR-
luciferase reporter construct (2.5µg) or the GRE-luciferase reporter construct (2.5µg) and 
varying doses of pVpr (0.1-5.0µg) in order to determine the optimal transactivation response.  
For the CV-1 cell line, phGRα was co-transfected (2.0µg) with reporter and Vpr or vector 
constructs. Forty-eight hours post-transfection, cells were washed and lysed using 500µL of 1X 
Reporter Lysis Buffer (Promega, Madison, Wisconsin). Cell lysates were spun down to remove 
cell debris and supernatant was collected for further use. Luciferase substrate was added to 20µL 
cell lysate. (Promega, Madison, Wisconsin).  Luciferase was analyzed for expression by a 
Veritas luminometer and results were based on Relative Light Units (RLU).  Protein estimation 
of the cell lysate was determined by the Bradford Protein Assay (Bio-Rad, Richmond, CA) and 
results were quantitated accordingly.  Transfection efficiency was normalized by transfecting 
with pEGFP and analyzed by fluorescence expression. 
  
Effects of Mifepristone on HIV-1 LTR or GRE-mediated Transactivation:  HeLa, CV-1, or 
HEK293 cells were co-transfected with the HIV-1 LTR-luc (2.5µg) or GRE-luc (2.5µg) reporter 
constructs in the presence of pVpr.  For CV-1 cell transfection, phGRα was also added (2.0µg).  
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 Mifepristone, mifepristone analogs, and/or dexamethasone were added twenty-fours hours prior 
to cell lysis in a dose-dependent manner.  Since mifepristone and analogs were solubilized in 
ethanol, all concentrations were in an equal volume to ensure that the presence of the solvent was 
not a variable to any results.  Forty-eight hours post-transfection, cells were washed in PBS and 
lysed in 500µL 1X Reporter Lysis Buffer.  Luciferase activity was measured by RLU and 
quantitated by protein estimation. 
 
4.9. PBMC Antiviral Assay 
 
PBMC Infection:  To determine the effects of mifepristone on wild-type infection, PBMCs were 
isolated as described and stimulated with PHA-P (5µg/mL) for three days.  After stimulation, 
cells were washed two times in PBS and resuspended in IL-2-containing media.  For viral 
infection, total cells were infected with an MOI of 0.1 of either the 89.6wt, pNL4-3,  or H112 
viruses for eight hours at 37˚C.  After infection, virus-containing media was removed and cells 
were washed two times in PBS and re-suspended in fresh IL-2-containing media.  Cells were 
plated in 6- or 12-well plates at 5 x 106 cells/well in a total volume of 3mL.  Mifepristone or its 
analogs or the EtOH control were added in a dose-dependent manner to each well directly after 
infection. Supernatant samples (500µL) were removed every two to three days at which time 
mifepristone, compounds, or EtOH were re-administered due to the half-life (48-72 hours) of the 
compounds.  To determine the concentration of viral p24, an ELISA (NIH, AIDS Vaccine 
Program, Frederick, MD) was performed as per the manufacturer’s directions.  
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 Pre-Cellular and Pre-Viral Treatment with Mifepristone:  In order to determine if 
mifepristone decreased transactivation of viral genes more efficiently when either the cells or the 
virus were pre-treated with mifepristone, prior to infection cells were washed in PBS and re-
suspended in IL-2-containing media.  For cellular pre-treatment, PBMCs  (5 x 106/well) were 
plated in 6- or 12-well plates in a total volume of 1mL and mifepristone was added in a dose-
dependent manner to the cell media for two hours at 37˚C prior to infection.  Cells were infected 
with an MOI of 0.1 of either 89.6wt, pNL4-3, or H112 viruses for eight hours at 37˚C.  Post-
infection, virus-containing media was removed and cells were washed two times in PBS.  Cells 
were re-suspended in 3mL of IL-2 containing media and mifepristone was re-administered to the 
cells in a dose-dependent manner similar to initial treatment with the compound.  Every two to 
three days, supernatant samples were collected for analysis by p24 and mifepristone was re-
administered in a dose-dependent manner.  For viral pre-treatment, virus-containing media was 
incubated at 37˚C in the presence of mifepristone in a dose-dependent manner for two hours.  
Post-incubation, virus-containing media in the presence of mifepristone was added to the cells at 
an MOI of 0.1 and incubated for eight hours at 37˚C.  After infection, cells were washed two 
times in PBS and re-suspended in IL-2-containing media.  Mifepristone was administered in a 
dose-dependent manner similar to initial treatment with the compound.  Samples were taken 
every two or three days for analysis by p24 ELISA and mifepristone was re-administered at that 
time. 
4.10. Macrophage Antiviral Assay 
 
Macrophage Infection: Monocyte-derived human macrophages were isolated from PBMCs by 
adhesion as described and plated in either 6- or 12-well plates.  After 7-10 days differentiation by 
29 
 GM-CSF and M-CSF, macrophages were infected with an MOI of 0.1 of either Ba-L, 89.6wt,  or 
H112 viruses for eight hours at 37˚C.  After infection, virus-containing supernatant was removed 
and cells were washed two times to remove excess virus.  1.5mL fresh macrophage media 
(DMEM supplemented with 10% FBS, 10% Human or horse serum, 1% penicillin-streptomycin, 
1% L-Glutamine) and 1.5mL media collected from macrophages prior to infection were added to 
the cells for a total volume of 3mL.  Mifepristone, compounds, or the EtOH control were added 
in a dose-dependent manner post-infection.  Supernatant samples were collected every two to 
three days for analysis by p24 ELISA and mifepristone, compounds, or the EtOH control were 
re-administered during that time. 
 
Pre-Cellular or Pre-Viral Treatment:  Prior to infection, cells were washed in PBS and 1mL 
macrophage media was added to the cells.  Mifepristone, mifepristone analogs, or the EtOH 
control were administered to the cell media in a dose-dependent manner for two hours at 37˚C 
pre-infection.  After the two-hour incubation, virus was added at an MOI of 0.1 of either Ba-L, 
89.6wt, or H112, and cells were incubated at 37˚C for eight hours.  Post-infection, virus-
containing media was removed and cells were washed two times in PBS.  1.5mL fresh 
macrophage media and 1.5mL macrophage media taken from cells prior to infection were added 
to the cells for a total volume of 3mL.  Mifepristone or the EtOH control were added in a dose-
dependent manner similar to original administration.  Supernatant samples (500µL) were taken 
every two to three days for p24 analysis and mifepristone or the EtOH control were re-
administered at that time. 
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4.11. CEM Antiviral Assay and FACS analysis 
 
To demonstrate the effects of mifepristone specifically within a T-cell population, 174xCEM T-
cells were infected with an MOI of 0.5 of the pNL4-3-EGFP wild-type virus for eight hours.  
Post-infection, cells were spun down and washed two times with PBS to remove all excess virus.  
Cells were plated in a 12-well plate (2.5x105/well) in a 2mL total volume and mifepristone was 
added in a dose-dependent manner to the cells.  Mifepristone was re-administered to the cells 
after two days and at three days post-infection, cells were collected, washed two times in FACS 
buffer (PBS, 1% FBS, 1% Sodium Azide) and fixed in 2% paraformaldehyde for 30 minutes at 
4˚C.  After fixation, cells were washed to remove paraformaldehyde, resuspended in 500µL 
FACS buffer, and analyzed by FACS analysis.      
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5. CHAPTER FIVE:  RESULTS 
 
5.1. AIM#1:   To Determine the Relationship between Vpr and GR and Their Resulting 
Role in Virus Replication 
 
 
5.1.1.  Effects of Vpr on Heterologous Transactivation 
 
It is well-established by our group and others that Vpr increases the transactivation of viral 
genes.  To demonstrate the effects of Vpr on viral gene transactivation, a luciferase reporter 
assay was utilized to measure the amount of transactivation occurring downstream from the 
heterologous promoter region, HIV-1 LTR.  The HIV-1 LTR promoter region was constructed 
upstream of a firefly luciferase gene therefore upon promoter activation, downstream genes are 
transactivated, resulting in the production of the luciferase enzymatic protein. When substrate is 
added to this luciferase protein, light wavelengths are emitted and are quantitated in the form of 
Relative Light Units (RLU).  To determine the effects of Vpr on promoter-driven transactivation, 
HEK293 or HeLa cells were co-transfected with the HIV-1 LTR-luciferase reporter construct 
(2.5µg) in the presence of varying doses of the Vpr expression plasmid (pVpr) (Figure 11).  
Figure 11 demonstrates that Vpr was able to increase the transactivation of heterologous 
promoter-controlled genes approximately 3.5-fold as represented by the downstream production 
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Figure 11. Effects of Vpr on HIV-1 LTR-mediated transactivation  The reporter construct, HIV-1 LTR-luc, was 
transfected in HEK293 cells in the presence of different concentrations of Vpr (0.1, 0.5, and 1.0µg) to 
determine the effects of Vpr on transactivation. Forty-eight hours post-transfection, cell lysates were analyzed 
for luciferase activity. pcDNA3.1 represents vector control; Vpr represents the Vpr expression plasmid. 
 
of luciferase driven by the HIV-1 LTR promoter.  These results exemplify that the presence of 
Vpr is able to increase the transactivation of the LTR promoter driven reporter in a dose-
dependent manner.  Since Vpr is present in the virion prior to the production of Tat, this initial 
transactivation may in part play a role in the initial production of viral proteins. 
 
5.1.2. Parameters for Transactivation Reporter Assays 
 
Initial transactivation studies prompted the analysis of the optimal concentrations of DNA to 
administer to the reporter-based transactivation models.  In order to ensure that the appropriate 
concentrations of plasmid DNA were transfected, and therefore achieve optimal transactivation, 
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 parameters were determined to standardize all luciferase reporter assays specifically in the 
presence of pVpr, as this protein demonstrates toxic behavior at higher concentrations. To 
investigate the appropriate concentrations of plasmid DNA, dose-dependent transactivation 
assays were conducted in which one specific parameter was varied in each set of assays in order 
to test for optimal reporter activity in the various cells lines.   
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Figure 12. Optimal Concentrations of pVpr for Reporter Transactivation Assays in Different Cell Types.  (A) 
HeLa, (B) CV-1, or (C) HEK293 cells were transfected with the heterologous promoter HIV-1 LTR in the 
presence of varying doses of pVpr.  Forty-eight hours post-transfection, cells were lysed and luciferase 
activity was determined as RLU.  Fold induction is represented.  All assays were conducted at least three 
times. 
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 Figure 12 demonstrates cell-dependent effects of varying doses of pVpr on HIV-1 LTR 
promoter-driven transactivation. In HeLa cells, the optimal concentration of pVpr was 0.5µg, 
leading to an approximate 3.5-fold Vpr-mediated increase in transactivation. CV-1 and HEK293 
cells demonstrated optimal concentrations at 0.25µg and 2.5µg leading to a 7-fold and 7.5-fold 
increase, respectively.  Similar results were noted when both the GRE-luciferase promoter 
construct and HIV-1 LTR-luc promoters were transfected.  All three cell types, HeLa, CV-1, and 
HEK293, demonstrated a loss of transactivation activity when the pVpr concentrations reached a 
higher level.  This could be due to the toxicity of Vpr at high concentrations.  Interestingly, this 
was also cell-dependent; HeLa cells lost transactivation activity at 1.0µg, CV-1 cells at 0.5µg, 
and HEK293 cells at 5µg concentrations. 
 
5.1.3. Vpr-Mediated Transactivation of the Autologous GRE Promoter 
 
Since the presence of Vpr increased transactivation in a dose-dependent manner, establishing the 
importance of Vpr to promoter-driven transactivation, it was important to next determine a 
mechanism by which Vpr was able to drive transactivation of promoter-driven genes.  The 
structure of Vpr includes three helices, each containing LxxLL motifs, which have been 
established as protein-interacting motifs, including in the context of transcription factors.   We 
had shown previously that Vpr interacted directly with GR, and that this interaction led to the 
transactivation of the cellular Glucocorticoid Response Element (GRE) promoter-driven genes 
(49,75).  To further exemplify that Vpr interacted with GR, and that this relationship led to 
promoter transactivation, reporter assays were conducted using the endogenously GR-negative 
cell line, CV-1 (Figure 13).  The heterologous promoter, GRE, was constructed as described 
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 containing the downstream luciferase reporter gene (GRE-luc).  CV-1 cells were co-transfected 
with pGRE-luc in the presence or absence of pGR.  When pGRE-luc was transfected without 
pGR, there was little to no promoter activation.  When pGR was added in the presence of pGRE-
luc alone, there was minimal transactivation.  However when pVpr was co-transfected with both 
pGRE-luc and pGR, transactivation increased in a dose-dependent manner up to 3-fold, 
demonstrating that Vpr-mediated transactivation occurred in the presence of GR.   
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Figure 13.  Effects of Vpr on the heterologous promoter, GRE.  CV-1 cells were transfected with the reporter 
construct GRE-luciferase in the presence of GR alone as well as in the presence of Vpr.  Forty-eight hours 
post-transfection, cells were lysed and analyzed for luciferase activity as determined by RLUs.  Results are 
shown as  fold induction with the vector alone control as one.  Results represent three separate experiments. 
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 5.1.4. Interaction between GR and Vpr Occurs at the LxxLL Motifs of Vpr 
 
To investigate the Vpr domains involved in the interaction between Vpr and GR, Vpr leucine 
mutants were constructed by site-directed mutagenesis as described (Figure 14).  
    
 
Figure 14. Representation of Leucine Mutants.  Diagram of leucine mutants as constructed by site-directed 
mutagenesis.  Leucines within the LxxLL motifs on each of the three helices of Vpr were point mutated to 
either alanine (A) or glycine (G).   
 
As was previously stated, each of the three Vpr helices contains the LxxLL motif, which have 
been shown to be involved in protein-protein interaction.  It is also known that several 
transcription factors are able to bind directly with this motif.  By mutating each of the leucines 
within the Vpr protein, if in fact GR did interact with these motifs, we hypothesized that this 
interaction could be disrupted when the LxxLL motifs were altered.   Using reporter 
transactivation assays, Vprwt and Vpr mutants were co-transfected with either the GRE-luciferase 
reporter construct or the HIV-1 LTR-luciferase reporter construct in both HeLa and CV-1 cells 
(Figure 15).  As demonstrated in Figure 15A and 15B, Vpr-mediated transactivation of GRE-
driven genes was altered in the presence of different Vpr mutants in both HeLa and CV-1 cell 
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 lines.  For example, the leucine mutant L22A increased transactivation approximately 11-fold.  
In contrast, the leucine mutants L42A and L67A decreased transactivation by 50% in comparison 
to wild-type Vpr.  Similar results were seen in Figure 15C and 15D in the context of Vpr-
mediated HIV-1 LTR promoter transactivation in both HeLa and CV-1 cells. 
 
 
Figure 15. Effect of HIV-1 Vpr leucine mutants on GRE and HIV-1 LTR-mediated Transactivation.  (A) HeLa 
cells were transfected with the GRE-luciferase reporter construct in the presence of Vpr and Vpr leucine 
mutants.  (B)  CV-1 cells were transfected with GRE-luciferase reporter construct in the presence of GR and 
Vpr mutants. (C) HeLa cells were transfected with the reporter construct HIV-1 LTR-luciferase in the 
presence of Vpr mutants.  (D)  CV-1 cells were transfected with the HIV-1 LTR-luciferase reporter, GR, and 
Vpr mutants. 
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5.1.5. Summary to Aim#1 
 
The focus of AIM#1 was to determine the role of Vpr in HIV-1 LTR-mediated transactivation. 
By utilizing the luciferase reporter assay, the presence of Vpr demonstrated an increase in HIV-1 
LTR-mediated transactivation in a dose-dependent manner.  Optimal transactivation parameters 
were determined, specifically in the context of pVpr, in order to accurately conduct all following 
reporter assays.  Furthermore, Vpr increased transactivation through the GRE region located 
within the HIV-1 LTR.  More specifically, Vpr was able to interact with the cellular 
Glucocorticoid Receptor, leading the transactivation of GRE-driven gene expression.  The 
LxxLL motifs found within the three helices of Vpr were implicated in the interaction with GR 
as determined by utilization of Vpr leucine mutants, leading to variances in transactivation levels 
of both HIV-1 LTR and GRE promoter-driven genes.
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5.2. Aim#2:  To assess whether the GR antagonist, mifepristone, is able to inhibit Vpr-
mediated transactivation and virus replication 
 
5.2.1. The Effects of Mifepristone on Vpr-mediated Transactivation 
 
The ability of Vpr to transactivate viral genes by hijacking the cellular transfection pathway 
utilized by GR, possibly initiating viral protein production by transactivating viral genes prior to 
the production of Tat, allows for the infiltration by an antiviral prohibiting or decreasing this 
transactivation.  The GR antagonist, mifepristone, is able to decrease GR-mediated 
transactivation of GRE-dependent downstream genes via several mechanisms (73).  In order to 
determine if mifepristone was able to inhibit the transactivation of viral genes driven by the HIV-
1 LTR promoter, a series of reporter assays were conducted to determine the effects of 
mifepristone on Vpr-mediated autologous promoter-activated gene transcription (Figure 16). The 
HIV-1 LTR-luciferase construct was transfected in the presence of Vpr in both HeLa (Figure 
16A) and HEK293 (Figure 16B) cell lines.  Results demonstrated that mifepristone was able to 
inhibit the transactivation of HIV-1 LTR-driven genes in a dose-dependent manner by greater 
than 95% at concentrations of 1, 5, and 10µM, thereby demonstrating the effectiveness of this 
compound in decreasing the Vpr-mediated transactivation of viral promoters as represented by 
HIV-1 LTR. 
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Figure 16. Effects of Mifepristone on HIV-1 LTR promoter activity.  (A) HeLa cells were transfected with HIV-
1 LTR and Vpr in the presence of different concentrations of mifepristone.  (B) HEK293 cells were 
transfected with HIV-1 LTR-luc in the presence of Vpr and varying concentrations of mifepristone.  Results 
represent the results of at least three separate experiments. 
 
5.2.2. Effects of Dexamethasone on Vpr-mediated Transactivation 
 
Under normal conditions, the cellular GR is held in the cytoplasm by chaperones.  Upon binding 
of ligand, heat shock proteins and other chaperones are dislodged from GR allowing the 
transcription factor to translocate into the nucleus and bind its associated promoter response 
element, GRE.  GR has also been shown to translocate into the nucleus without the presence of 
ligand and impact gene transactivation in a similar manner to that of ligand-bound GR.  In order 
0
0.5
1
1.5
2
2.5
3
Vec tor V pr 0 .5uM 1.0 uM 5.0uM 10 .0u M
Fo
ld
 A
ct
iv
at
io
n
Conc entra tion  o f Mi fe pris tone
Conc entra tion  o f Mi fe pris tone
+ HIV -1 LT R-l ucifera se
+  HIV -1  L TR -luc ife ras e
A .
B .
Fo
ld
 A
ct
iv
at
io
n
Fo
ld
 A
ct
iv
at
io
n
41 
 to determine the role of ligand in Vpr-mediated transactivation, it was important to first establish 
what role the hormones and steroids in the cell media played in Vpr-mediated transactivation.  A 
series of reporter assays were thus conducted, in both HEK293 and CV-1 (no endogenous GR 
present) cell lines, in the presence of either DMEM supplemented with 10% fetal bovine serum 
(FBS) or in DMEM supplemented with charcoal-dextran-treated stripped serum (stripped), in 
which the majority of hormones and steroids were removed (Figure 17).   
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Figure 17. Effects of Media on Vpr-mediated Transactivation.  (A) HEK293 cells were transfected with HIV-1 
LTR-luciferase in the presence of Vpr in both DMEM supplemented with 10% FBS (FBS) and DMEM 
supplemented with 10% dextran charcoal-stripped serum (stripped).  (B)  CV-1 cells were transfected with 
HIV-1 LTR-luciferase in the presence of Vpr in both DMEM supplemented with 10% FBS (FBS) or DMEM 
supplemented with 10% dextran charcoal-stripped serum (stripped).  Results reflect at least three separate 
experiments in each cell line. 
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 Results demonstrated that in the presence of either FBS-supplemented DMEM or dextran 
stripped-supplemented DMEM, HEK293 cell transactivation only varied slightly, with greater 
dose-dependent Vpr-mediated transactivation demonstrated in FBS-containing media (Figure 
17A). In the presence of stripped serum, there was slight elevation of transactivation levels, 
noted also in the vector control (HIV-1 LTR-luciferase alone).  In the case of CV-1 transfection 
(Figure 17B), there was a significant increase in the amount of transactivation demonstrated 
when cells were transfected in stripped serum; transactivation increased an average of 3-4-fold.  
Because the stripped serum lacked steroid and hormone ligand for GR to bind thereby enforcing 
the transactivation of GRE-controlled genes, it is unknown as to why there was such an increase 
in transactivation of the reporter gene.  Quite possibly, other factors which limit GR-controlled 
transactivation, such as NF-ĸB, are also prevented from entering the nucleus thereby preventing 
the control of GR-mediated transactivation of NF-ĸB-regulated gene expression.   
 
To futher determine the extent to which ligand influences Vpr-mediated transactivation, the 
steroid dexamethasone was used, a well-known and well-proven agonist of GR-mediated 
transactivation.  Our group had shown previously that Vpr and dexamethasone bind GR and 
mediate the GR interaction with GRE in a similar manner (49).   In order to establish if Vpr and 
dexamethasone transactivate HIV-1 promoter-driven genes in a similar manner, HEK293 cells 
were transfected with the reporter HIV-1 LTR-luc in the presence of either Vpr or 
dexamethasone or both Vpr and dexamethasone (Figure 18).   
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Figure 18. Comparison between the Effects of Vpr and Dexamethasone on HIV-1 LTR-driven transcription.  
HEK293 cells were transfected with HIV-1 LTR-luciferase in the presence of either Vpr, dexamethasone, or 
both.  Forty-eight hours post-transfection, cells were lysed and assayed for luciferase expression.  Results are 
representative of three separate trials. 
 
Results indicated that Vpr was able to transactivate GRE- or HIV-1 LTR-driven transactivation 
in a dose-dependent manner similar to that of dexamethasone, correlating with results previously 
demonstrated by EMSA (49).  Since it was not known exactly where Vpr binds GR, it was 
unknown as to if the mediating of transactivation would occur in a competitive manner, or in an 
additive manner.  To investigate this further, HEK293 cells were transfected with the reporter 
HIV-1 LTR-luc in the presence of Vpr, and Vpr and dexamethasone added together (Figure 19). 
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Figure 19. Vpr and Dexamethasone Transactivate HIV-1 LTR-promoted transcription in an additive manner.  
HEK293 cells were transfected with HIV-1 LTR-luc in the presence of Vpr or Vpr and dexamethasone.  
Results reflect the analyses of at least three separate experiments. 
 
Results indicated that dexamethasone and Vpr were able to increase transactivation of HIV-1 
LTR-driven genes in an additive manner.  Interestingly, when both Vpr and dexamethasone were 
added together, there was a saturation in promoter activity.  In other words, when both Vpr and 
dexamethasone were added with increasing concentrations, there was no further increase in 
transactivation.  Taken together, it is possible that Vpr and dexamethasone do not bind in the 
same ligand-binding domain pocket and are therefore are able to instigate HIV-1 LTR-driven 
transactivation in an additive manner. 
 
Dexamethasone and mifepristone share a binding pocket in the ligand binding domain (LBD) of 
the glucocorticoid receptor.  To determine if mifepristone would be able to inhibit the 
transactivation of  HIV-1 LTR-driven genes in the presence of both Vpr and dexamethasone, 
HIV-1 LTR-luc was transfected in the presence of pVpr in HeLa and HEK293 cells (Figure 20). 
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Figure 20. Effects of Mifepristone on Vpr + Dexamethasone-Mediated Transactivation.  (A) HeLa or (B) 
HEK293 cells were transfected with the HIV-1 LTR-luc promoter construct in the presence of both Vpr and 
Dexamethasone (1µM).  Mifepristone was added in a dose-dependent manner.  Forty-eight hours post-
transfection, cells were lysed and analyzed for luciferase activity.   
 
Even when both Vpr and dexamethasone, two complimenting agonists of GR, were present, 
mifepristone was able to inhibit transactivation of HIV-1 LTR-driven genes in a dose-dependent 
manner.  While there was slight inhibition of transactivation demonstrated when both Vpr and 
dexamethasone were present in HeLa cells (Figure 20A), mifepristone was still able to inhibit 
transactivation by  >90% in HEK293 cells (Figure 20B).  These results demonstrated the effects 
of mifepristone even when both Vpr and dexamethasone instigated HIV-1 LTR promoter-driven 
transactivation. 
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5.2.3. Cytotoxicity of Mifepristone 
 
To assess the toxicity of mifepristone in vitro, trypan blue exclusion or MTT assays were 
conducted in HeLa, HEK293, CV-1, PBMCs, and monocyte-derived macrophages for three days 
as described (Table 4). For both PBMCs and macrophages, cytotoxicity was measured for one 
week to determine if mifepristone was toxic when more than one dose was administered 
(mifepristone was added every three days as described) (Figure 21).  For the seven-day PBMC 
trypan blue exclusion assay, cells were infected with either 89.6wt  virus or the patient isolate 
H112 virus in the presence of mifepristone.  Results indicated that even after seven days in the 
presence of mifepristone, both PBMCs and macrophages demonstrated little cell death, with the 
exception of the 10µM dose of mifepristone administered to PBMCs, which after one week 
resulted in 80% toxicity.   
  CT25 (µM) CT50 (µM) CT95 (µM) 
HeLa 25 35 50 
HEK293 12 50 95 
CV-1 20 48 80 
Macrophage 75 100 200 
PBMC 5 25 45 
 
Table 4.  In Vitro Cytotoxicity of Mifepristone. Three-day MTT assay was conducted as described in HeLa, 
HEK293, CV-1, monoctye-derived macrophages, and PBMCs.  Results reflect concentration dose to incur 
25% cytotoxicity (CT25), 50% cytotoxicity (CT50), and 95% cytotoxicity (CT95). 
 
 
 
47 
  
 
 
Figure 21. Percent Viability of Mifepristone after Seven Days.  (A)  PBMCs.  Percent Viability of PBMCs was 
determined through trypan blue exclusion while infected using two separate viruses.  (B) Macrophages.  
Percent Viability was determined by MTT assay as described.   
 
5.2.4. Effects of Mifepristone on Virus Infection 
Vpr-mediated transactivation occurs through the interaction of Vpr with the cellular 
Glucocorticoid Receptor.  By use of the GR antagonist mifepristone, the transactivation of HIV-
1 LTR promoter-driven genes is able to be repressed by greater than 90%.  In assessing 
mifepristone for its efficacy as compound with possible antiviral properties, a series of infection 
assays were conducted in CEMx174 (established T cell line), PBMCs, and monocyte-derived 
macrophages to determine if, in fact, mifepristone was able to inhibit replication-competent 
viruses of different tropism. 
0
20
40
60
80
100
120
0 1 2.5 5 10
Mifepristone Concentration (uM)
 V
iab
ilit
y 
(%
)
0
20
40
60
80
100
120
0 10 50 100 500
Mifepristone Concentration (uM)
 V
ia
bi
lit
y 
(%
)
(A ) 
(B ) 
 V
iab
ilit
y 
(%
)
 V
ia
bi
lit
y 
(%
)
48 
  
5.2.4.1. Antiviral Properties of Mifepristone in the established T-cell line, CEMx174 
 
 
In order to determine if mifepristone could inhibit viral replication in T cells, the T-cell line 
CEMx174 was infected with the NL4.3wt virus which also expressed the fluorescent protein 
EGFP (NL4.3-EGFP) at an MOI of 0.5.  Eight hours post-infection, cells were washed to remove 
unbound virus and mifepristone was added to the cells in a dose-dependent manner.  At day 
three, cells were analyzed for the expression of EGFP as a measure of virus replication. Figure 
22 demonstrates a dose-dependent decrease in cell infectivity in the presence of mifepristone as 
determined by FACS analysis.  Mifepristone, when administered at a 10µM concentration, was 
able to inhibit viral replication by as much as 88% compared to the untreated culture or vehicle-
treated culture.  Even at the 0.5µM concentration, mifepristone was able to inhibit viral 
replication by 51%.  FACS analysis also demonstrated little to no cell death in the presence of 
mifepristone at the 3-day timepoint, exemplifying that there were no toxic effects that played a 
role in the inhibition of viral replication.  To further confirm these results, p24 samples were 
taken at the time of FACS analysis (Figure 23).  Results demonstrated by p24 that mifepristone 
was able to inhibit the production of p24 in a dose-dependent manner. 
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 No Infection                   No Drug                      Ethanol
 
Figure 22.  Effects of Mifepristone on NL4-3-EGFP infection as determined by FACS analysis.  CEM cells were 
infected with an MOI of 0.5 of the EGFP-expressing wild-type NL4-3 virus.  Mifepristone was added post-
infection in a dose-dependent manner.  Samples were taken three days post-infection and analyzed by FACS 
analysis. Percentages reflect the number of cells infected.  Results are representative of two separate 
experiments. 
 
 
Figure 23.  Effects of Mifepristone on CEMx174 infected with NL4-3-EGFP by p24 analysis.  CEM were 
infected with the NL4-3 virus at an MOI of 0.5 and treated with mifepristone in a dose-dependent manner. 
Three days post-infection, samples were taken and analyzed by p24 ELISA. 
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5.2.4.2. Antiviral Effects of Mifepristone in PBMCs Infected with Replication 
Competent   Dual-tropic 89.6 Virus 
 
 
To further assess the properties of mifepristone as an antiviral in the context of infection in 
primary cells, PBMCs from normal healthy donors were isolated by the lymphocyte gradient 
isolation method.  The virus isolate, 89.6, is a commonly used strain to demonstrate wild-type 
infection as it is dual-tropic in nature and therefore able to infect both X4 and R5 receptor-
expressing cells, including both T-cells and macrophages.  PBMCs were stimulated with PHA-P 
(5ug/mL) for three days.  Post-stimulation, cells were infected with the 89.6wt virus at an MOI of 
0.1 for eight hours.  Cells were then washed two times in PBS to remove excess virus.  PBMCs  
were cultured at a concentration of 5 x 106 and mifepristone was added in a dose-dependent 
manner.  Supernatant samples were taken every two to three days for p24 analysis and 
mifepristone was re-administered at that time.  Figure 24 shows that mifepristone was able to 
inhibit viral replication in a dose-dependent manner in three separate donors.  The highest 
concentrations of mifepristone, 10 and 5µM inhibited viral replication by greater than 90%, 
similar to results seen in transactivation assays. 
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Figure 24.  Antiviral Effects of Mifepristone on 89.6wt-infected PBMCs in three separate donors.  PBMCs were 
infected with an MOI of 0.1 of the dual-tropic 89.6.  Post-infection, mifepristone was added in a dose-
dependent manner and supernatant samples were collected every two or three days and analyzed for p24.  
Panels A-C represent the antiviral effect of mifepristone in PBMCs from different donors. 
 
5.2.4.3. Antiviral Effects of Mifepristone on PBMCs infected with the Patient Isolate, 
H112 
 
To further determine if mifepristone would be able to inhibit viral replication of primary isolates, 
PBMCs were infected with the patient isolate H112.  Briefly, PBMCs were infected with the 
H112 isolate at an MOI of 0.1 for eight hours.  Mifepristone was administered in a dose-
dependent manner to the cells and samples were removed every three days for analysis by p24 
ELISA (Figure 25).  Results demonstrate that mifepristone is able to inhibit viral replication of 
this patient isolate in a dose-dependent manner.  While viral replication is not totally inhibited by 
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 mifepristone at the 10µM concentration as was demonstrated in previous experiments using 
89.6wt , this concentration was able to prevent viral replication by 85% while the 5µM 
concentration was able to prevent replication by approximately 45%.   
 
Figure 25.  Antiviral Effects of Mifepristone on PBMCs infected with the Patient Isolate H112.  PBMCs were 
infected with an MOI of 0.1 of the patient isolate H112 virus.  Mifepristone was added in a dose-dependent 
manner and samples were collected every three days and assessed for the presence of p24.  Results 
representative of two separate experiments. 
 
 
5.2.4.4. Antiviral Effects of Mifepristone in Human Macrophages Infected with the 
Macrophage-Tropic  Viral Isolate, Ba-L 
 
 
As was previously stated, macrophages are initial targets of HIV-1, specifically in mucosal 
tissues (45).  Vpr has been shown to be necessary for the infection of macrophages (42-44).  
Therefore, the finding of an antiviral specifically targeting Vpr-mediated viral replication could 
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 possibly prevent and/or decrease the infection of these target cells.  To assess the antiviral 
properties of mifepristone in macrophages, infection using the R5-tropic virus Ba-L was 
conducted to determine if similar results of dose-dependent mifepristone inhibition, as seen in 
both T-cells and PBMCs, could also occur in the infection of macrophages.  Macrophages were 
isolated by adherence, as described in methods.  Briefly, normal human PBMCs were isolated 
using the lymphocyte gradient isolation method.  Directly after isolation, PBMCs were plated in 
either 6- or 12-well plates (3.5 x 106 or 1.5 x 106 PBMCs per well, respectively) for two hours, 
during which time the monocytes adhered to the plates, consisting of approximately 10% of the 
total PBMC population.   Non-adherent cells were removed.  Monocytes were differentiated into 
macrophages for approximately eight to ten days by the addition of GM-CSF and M-CSF, 
macrophage-stimulating cytokines. After monocytes were fully matured into macrophages, 
which was determined by both CD14 staining and cell morphology, macrophages were infected 
with an MOI of 0.1 of the Ba-Lwt virus for eight hours.  Post-infection, cells were washed to 
remove all virus and mifepristone was added in a dose-dependent manner.  Supernatant samples 
were taken every two to three days, and mifepristone was re-administered to the cells at the time 
of sample collection.   Figure 26 demonstrates the effects of mifepristone on macrophage 
infection with Ba-L virus. 
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Figure 26. The Effects of Mifepristone on Macrophage Infection with the  Ba-L Virus Isolate.  Monoctye-
derived macrophages were infected with an MOI of 0.1 Ba-Lwt.  Post-infection, mifepristone was added to the 
cells in a dose-dependent manner.  Supernatant samples were collected every three days and assessed for the 
presence of p24.  Results are representative of three separate experiments.  
 
Results from Figure 26 indicate that similar to T-cell and PBMC infection with wild-type virus, 
mifepristone inhibits the replication of macrophage-tropic Ba-L virus in the context of macrophage 
infection.  At a 5µM concentration of mifepristone, infection was inhibited by greater than 70% 
compared to the untreated control.  These results further support the antiviral effect of 
mifepristone in macrophages, in a manner similar to established CD4+ T cells and primary 
PBMCs.
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 Summary for AIM#2 
 
The GR antagonist, mifepristone, was tested as a possible antiviral compound interrupting the 
Vpr-mediated transactivation of genes promoted by the HIV-1 LTR promoter specifically 
through the GRE promoter region.  It was established both in reporter transactivation models, 
and in antiviral models, that mifepristone disrupted HIV-1 LTR-promoted transactivation and 
thereby inhibited the replication of HIV-1.  The ability of mifepristone to disrupt Vpr-mediated 
transactivation in the context of GR demonstrates a possible mechanism for antiviral treatment. 
Combined with low toxicity levels established in primary cells, mifepristone has the potential of 
becoming a new antiviral, adding a new class of therapeutics to the currently used therapies.  The 
next chapter with futher discuss the potential of mifepristone in clinical application by analyzing 
the effects of this compound on viral re-activation from latency as well as investigate the 
possibility of utilizing mifepristone analogs as therapeutics. 
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5.3. AIM#3:  Clinical Applications of Mifepristone 
 
5.3.1. Pre- versus Post-Treatment with Mifepristone 
 
The hope for mifepristone originated with the idea that this compound could be used not only to 
treat infection, but to prevent infection as well.  Initial studies included adding mifepristone post-
infection, and not prior to or during infection.  While most antivirals are used to treat patients 
post-infection, few are used in emergency prophylaxis, such as AZT, and none are currently 
utilized as a preventative drug.  Since mifepristone is able to inhibit Vpr-mediated 
transactivation, this compound holds the possibility of being used to prevent infection by not 
allowing the initial transactivation of viral-promoted genes, especially in the context of 
macrophages where the presence of Vpr is imperative for infection.  To determine if 
mifepristone was able to inhibit the infection of cells when the compound was present either 
prior to or during infection, assays were constructed to compare the amount of inhibition of viral 
infectivity in the presence of mifepristone.  Furthermore, virus was also pre-treated with 
mifepristone to determine the effects of viral replication in the context of compound-treated 
virus. 
 
5.3.1.1. Pre-Treatment of PBMCs and Macrophages with Mifepristone Prior to 
Infection 
 
 
To assess the difference between pre-treatment of PBMCs prior to and during infection and post-
treatment of PBMCs after infection, cells at a concentration of 5 x 106 were treated with 
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 mifepristone in a dose-dependent manner two hours prior to infection with 89.6wt virus.  
Similarly, monoctye-derived macrophages were pre-treated with mifepristone for two hours prior 
to infection with the macrophage-tropic Bal virus.  During the eight-hour infection, mifepristone 
was present in the media to ensure the presence of the compound throughout the process of 
infection.  Post-infection, cells were washed and mifepristone was re-administered in a dose-
dependent manner.  As controls, a second set of PBMCs or macrophages were infected 
simultaneously with the pre-treatment PBMCs without the presence of mifepristone. Post-
infection, cells were washed and mifepristone was added in a dose-dependent manner.  Similar to 
previous antiviral experiments, supernatant samples were collected every two to three days and 
assessed for the presence of p24 by ELISA (Figure 27). 
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Figure 27. Pre-Treatment versus Post-Treatment of PBMCs and Macrophages with Mifepristone. (A) PBMCs  
were pre-treated with mifepristone prior to and during infection and compared to (B) PBMCs treated with 
mifepristone post-infection.  (C) Macrophages pre-treated with mifepristone prior to and during infection 
compared to (D) Macrophages treated with mifepristone post-infection. Supernatant samples from both sets 
of PBMCs and macrophages were taken every three days and analyzed for the presence of p24. Results are 
representative of at least two experiments for both PBMCs and macrophages. 
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Results presented in Figure 27 demonstrated no significant difference between pre- and post-
treatment of cells with mifepristone either in PBMCs (panels A and B) or monocyte-derived 
macrophages (panels C and D).   Further studies need to be conducted to determine if, in fact, 
mifepristone is able to inhibit viral replication to a greater extent when cells are pre-treated with 
this compound prior to infection.   
 
5.3.1.2. Effects of Pre-Treatment of the Virus in Comparison to Cell Pre-Treatment in 
PBMCs 
 
 
Mifepristone has been demonstrated to alter the effects of transcription in several ways, 
including recruiting different co-factors to the transcriptional machinery and altering the 
conformation of GR around GRE, slowing down the transcriptional process.  In order to 
determine if mifepristone could work through a different mechanism directly affecting the virus, 
PBMCs were pre-treated with a dose-dependent regimen of mifepristone two hours prior to 
PBMC infection with the dual-tropic 89.6wt virus.  Cells were infected for eight hours, washed 
to remove excess virus, and mifepristone was added post-infection.  To compare the effects of 
viral pre-treatment to cellular pre-treatment, a second set of PBMCs were similarly pre-treated 
with a dose-dependent regimen of mifepristone for two hours, infected in the presence of 
mifepristone for eight hours, washed to remove excess virus, and mifepristone was re-
administered in a dose-dependent manner.  Supernatant samples were removed from both sets at 
three-day intervals and analyzed by p24 ELISA; mifepristone was re-administered in a dose-
dependent manner at that time (Figure 28). 
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Figure 28.  Effects of Mifepristone on Viral Pre-Treatment in Comparison to Cellular Pre-Treatment in PBMCs.  
(A)  PBMCs were infected with an MOI of 0.1 of the wild-type 89.6 which had been pre-treated in a dose-
dependent manner with mifepristone.  (B) PBMCs were pre-treated with mifepristone in a dose-dependent 
manner and subsequently infected with an MOI of 0.1 of 89.6wt.  Supernatant samples were removed every 
three days and assessed for the presence of p24. 
 
Results from this experiment demonstrated that 89.6wt virus pre-treatment in comparison to 
PBMC pre-treatment with mifepristone yielded no significant difference in viral replication post-
infection.  Therefore, there is no conclusive evidence demonstrating the viral pre-treatment with 
mifepristone is able to increase the inhibition of viral replication in the context of explicative 
virus.   
 
5.3.2. Effects of Mifepristone on Latent Viral Reservoirs 
 
 
One of the mechanisms in which HIV-1 remains elusive to total viral clearance during therapy is 
due to its ability to establish viral reservoirs (19-22).  In order to determine if mifepristone was 
able to prevent reactivation from latency, the promonocytic cell line U1/HIV-1 was used.  This 
cell line contains two copies of the proviral HIV-1 DNA which upon stimulation by viral 
proteins or other factors such as TNF-α, leads to the production of virus, which can be 
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 quantitated by p24 ELISA (86,87).  In this setting, U1/HIV-1 cells are able to be defined as latent 
HIV-1 reservoirs.  To establish if mifepristone was able to prevent the re-activation of the 
proviral DNA contained within the U1/HIV-1 cells, cells were activated by both TNF-α and by 
AT-2-treated inactivated NL4-3 virus. Therefore, any activation by the AT-2 inactivated virus is 
due to the presence of viral proteins in the particle and not due to infection.  Mifepristone was 
added in a dose-dependent manner during activation by both TNF and AT-2 –treated virus 
(Figure 29).  Results demonstrated that both U1/HIV-1 cells activated by TNF-α and AT-2 -
treated NL4-3 virus led to the production of p24, which was inhibited in a dose-dependent 
manner by mifepristone.  Interesting to note, the addition of EtOH (used as a vehicle control) 
increased viral production by the U1/HIV-1 cells, demonstrating further the effectiveness of 
mifepristone.   
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Figure 29.  Effects of mifepristone on re-activation from latency as determined by U1/HIV-1 viral production.  
(A) TNF-alpha stimulated U1/HIV-1 cells or (B) AT-2 treated U1/HIV-1 cells.  Cells were treated with 
mifepristone in a dose-dependent manner.  Virus replication was assayed on day three following activation 
and samples were assessed for the presence of p24. 
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 5.3.3. The Effects of Mifepristone Analogs on Promoter Transactivation and Antiviral     
Activity 
 
 Mifepristone is able to inhibit the transactivation of GRE-driven downstream genes, and 
consequently is able to inhibit the transactivation of LTR-driven downstream genes, thereby 
preventing viral gene expression.  Mifepristone binds to the glucocorticoid receptor in a manner 
similar to that of dexamethasone, binding in the same pocket within the ligand binding domain of 
GR in a competitive manner.  To identify a more potent and less toxic compound, we 
collaborated with the NCI drug discovery program.  Based on the structure of mifepristone, 
analogs were composed with slight differences in structure (Figure 30).  To determine if 
mifepristone analogs, similar to mifepristone with few molecular changes, would work in a 
manner similar to that of mifepristone, possibly with better efficacy in preventing viral 
transcription, several mifepristone analogs were assessed for their ability to inhibit HIV-1 LTR-
transactivation by Vpr. 
 
A. B.
D.C.
Figure 30.  Structure of mifepristone analogs.  (A) Analog 666510, (B) Analog 92336, (C) Analog 641295, and 
(D) Analog 15432. 
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5.3.3.1. Cytotoxicity of Mifepristone Analogs 
 
As these mifepristone analogs were previously unexplored compounds, MTT cytotoxicity assays 
were performed as described to determine if these analogs would prove to be toxic to HeLa, 
PBMCs, or macrophages (Figure 31).  The CT50 of analogs in PBMCs and HeLa cells is 
approximately 45µM, in macrophages approximately 60µM.  In comparison, the CT50 in the 
presence of mifepristone is approximately 35µM in HeLa, 25µM in PBMCs, and 100µM in 
macrophages.  Therefore, in PBMCs and HeLa these analogs are less toxic when compared to 
mifepristone however in macrophages there is an increase in toxicity demonstrated in the 
presence of analogs. 
(B)(A)
Figure 31.  Cytotoxic effect of mifepristone analogs in PBMC, HeLa, and Macrophages.  MTT assays were 
performed as described in methods in  (A) PBMC, (B) HeLa, and (C) Macrophages.  Percent viability (%) 
was calculated based on considering untreated cells as 100%.  Results reflect average of at least three 
separate experiments. 
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 5.3.3.2. Effects of Mifepristone Analogs on Promoter-Driven Transactivation 
 
In order to assess whether or not mifepristone analogs inhibited the transactivation of either 
autologous or heterologous promoters, a series of reporter assays were established in HeLa, CV-
1, and HEK293 cell lines. Briefly, the reporter constructs GRE-luciferase or HIV-1 LTR-
luciferase were transfected with pVpr (and pGR in the context of CV-1) and a dose-dependent 
concentration of mifepristone analogs in these cell lines.  Figure 32 demonstrates the effects of 
mifepristone analogs on HIV-1 LTR promoter transactivation in HeLa cells.  Initial experiments 
were conducted on each of the compounds to determine their effects on transactivation.  All 
compounds demonstrated a dose-dependent decrease in transactivation similar to mifepristone, 
though not all compounds inhibited transactivation to the same degree. 
 
Figure 32. Effects of Mifepristone Analogs on HIV-1 LTR Transactivation in HeLa Cells.  (A)  Comparison of 
the effects of analogs 92336, 66510, 641295, and 671271 on HIV-1 LTR-driven transactivation.  (B) Dose-
dependent effect of analog 92336 on HIV-1 LTR-driven transactivation.  (C)  Dose-dependent effect of analog 
641295 on HIV-1 LTR-driven transactivation.  Fold activation is calculated considering the vector control as 
one. 
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 Similar results were demonstrated in CV-1 cells.  Cells were transfected with HIV-1 LTR and 
Vpr in the presence of 10µM of mifepristone and analogs.  Post-transfection, cell lysates were 
analyzed for the presence of luciferase.   Percent inhibition was calculated for compounds 
mifepristone, 641295, 666510, and 92336.  Results demonstrated that mifepristone was able to 
inhibit viral transactivation at a greater extent in CV-1 cells than the mifepristone analogs 
(Figure 33). 
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Figure 33.  Effects of Mifepristone and Analogs on HIV-1 LTR-mediated transactivation in CV-1 cells.  CV-1 
cells were transfected with the HIV-1 LTR luciferase reporter construct in the presence of pVpr and pGR.  
Cell lysates were analyzed for the presence of luciferase. 
 
While mifepristone analogs do inhibit transactivation, a comparison to the inhibition induced by 
mifepristone on viral transactivation demonstrates that mifepristone decreases transactivation 
more effectively (greater than 90% inhibition by mifepristone, and only 15-60% inhibition by 
analogs 641295, 666510, and 92336) in CV-1 cells.   
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 Final transactivation studies to determine the effectiveness of mifepristone analogs on HIV-1 
LTR-driven transcription included the addition of dexamethasone.  Dexamethasone, which, as 
stated before, acts as ligand similar to cortisol, increases transactivation by binding to the 
glucocorticoid receptor and subsequently transactivating genes downstream of the GRE promoter 
region.  In order to determine if mifepristone analogs would be able to interfere with HIV-1 LTR 
promoter transactivation, CV-1 or HEK293 cells were transfected with the HIV-1 LTR-
luciferase reporter construct in the presence of pVpr, pGR in CV-1 cells, and the addition of 
dexamethasone 24 hours prior to cell lysis (Figure 34).  Results indicated that mifepristone 
analogs, while able to inhibit the transactivation of HIV-1 LTR-driven genes, were not able to 
inhibit transactivation to the extent that was seen when mifepristone was added.    
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Figure 34.  Effects of Mifepristone Analogs on HIV-1 LTR-mediated transactivation in CV-1 and HEK293 cells.  
(A)  CV-1 cells were co-transfected with the HIV-1 LTR luciferase construct in the presence of pGR and 
pVpr.  Mifepristone and analogs were added at a concentration of 10µM in the presence of dexamethasone. 
(B) HEK293 cells were transfected with HIV-1 LTR luciferase in the presence of pVpr.  Mifepristone and 
analogs were added at a 1µM concentration and dexamethasone was added 24 hours prior to cell lysis.  (C) 
HEK293 cells were transfected with the HIV-1 LTR luciferase in the presence of pVpr.  Mifepristone and 
analogs were added at a 10µM concentration and dexamethasone was added 24 hours prior to cell lysis.  
Forty-eight hours post-transfection, cells were lysed and luciferase concentration was determined.  Final 
results are presented as fold induction, the HIV-1 LTR control as having a fold of one. 
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 5.3.3.3. Effects of Mifepristone Analogs on Virus Infection in PBMCs 
 
After determining that mifepristone analogs were able to inhibit the transactivation of the HIV-1 
LTR promoter-driven genes, antiviral assays were performed using NL43wt-infected PBMCs.  
Cells were infected with virus for eight hours and washed to remove all residual virus.  Post-
infection, cells were treated with  similar doses of mifepristone and analogs.  Samples were taken 
after three days and assessed for inhibition of viral replication (Figure 35). 
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Figure 35. Three-day Effects of Mifepristone Analogs on NL4.3 wild-type infection of PBMCs.  Cells were 
infected with an MOI of 0.1.  Post-infection, mifepristone and analogs were administered in (A)1.0uM and (B) 
0.5uM concentrations.  Supernatant samples were taken at day 3 and assessed for the presence of p24. 
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 Results demonstrated that analogs were able to inhibit wild-type virus in PBMCs.  At a 1µM 
concentration (panel A), analogs 92336 and 66510 were able to inhibit virus greater than 90%.  
At a 0.5µM concentration, however (panel B), only mifepristone was able to inhibit viral 
replication greater than 90%.  
 
To further determine the effects of mifepristone analogs in virus infection, PBMCs were infected 
with 89.6wt for eight hours and post-infection mifepristone analogs were added at a concentration 
of 1µM (Figure 36).  The analog 671271 which is included in this study is AZT and was used
as a blind-folded control. 
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Figure 36.  Effects of Mifepristone Analogs on Viral Replication in PBMCs infected with 89.6.  PBMCs were 
infected with an MOI of 0.1 of the dual-tropic 89.6 wild-type virus.  Post-infection, compounds were added at 
a 1uM concentration.  Every three days, supernatant samples were collected and assessed for the presence of 
p24.   
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 Results demonstrated that the mifepristone analog 92336 was able to inhibit viral replication by 
80%.  Analogs 641295 and 66510 were able to inhibit virus by 70 and 60%, respectively. 
Therefore, it is possible to conclude that mifepristone analogs are able to inhibit viral replication 
in a manner similar to that of mifepristone, however mifepristone inhibits replication at a higher 
efficiency. 
 
 
5.3.3.4. Effect of Mifepristone Analogs on Ba-L Macrophage Infection 
 
In order to fully determine the effects of mifepristone analogs on viral infection, macrophages 
were infected with the Ba-L virus and the inhibitory effects of mifepristone analogs were 
analyzed.  Monoctye-derived macrophages were infected with an MOI of 0.1 for eight hours.  
Post-infection, cells were washed to remove residual virus and mifepristone analogs were added 
in a dose-dependent manner.  Every three days supernatant samples were collected, analogs were 
re-administered, and p24 analysis was conducted to determine the presence of viral peptides 
released in the media.  Figure 37 demonstrates the effects of each compound individually on 
macrophage infection based on a dose-dependent regimen. 
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Figure 37.  Effects of Mifepristone Analogs on Macrophages infected with Ba-L.  Macrophages were infected 
with an MOI of 0.1 of the wild-type Ba-L virus.  Post-infection, mifepristone analogs were added in a dose-
dependent manner.  Supernatant samples were collected every three days and analyzed for p24 by ELISA.   
 
Results demonstrated the dose-dependent inhibition of virus replication by individual analogs.  
With the exception of 10µM, other concentrations, while still maintaining dose-dependent 
inhibition, are not able to completely inhibit the virus.  This assay was conducted using two 
separate donors with similar results. 
 
 
 
 
 
 
0
1000
2000
3000
4000
5000
0 3 6 9
Days Post-Infection
p2
4 (
pg
/m
L)
10 uM
5 uM
1 uM
0.5 uM
0.1 uM
0.05 uM
No Treatment
0
1000
2000
3000
4000
0 3 6 9
Days Post-Infection
p2
4 (
pg
/m
L)
10 uM
A 5 uM
1 uM
0.5 uM
0.1 uM
0.05 uM
No Treatment
B
0
1000
2000
3000
4000
0 3 6 9
Days Post-Infection
p2
4 (
pg
/m
L)
10 uM
5 uM
1 uM
0.5 uM
0.1 uM
0.05 uM
No
Treatment
C 
0
1000
2000
3000
4000
0 3 6 9
Days Post-Infection
p2
4 (
pg
/m
L)
10 uM
5 uM
1 uM
0.5 uM
0.1 uM
0.05 uM
No
Treatment
D
71 
 5.3.4. Summary to AIM#3 
 
Because viral reservoirs are often established within macrophages, mifepristone was analyzed for 
the ability to prevent the reactivation of virus from latency using the promonocytic U1/HIV-1 
cell line.  Results demonstrated in a dose-dependent manner that mifepristone was able to inhibit 
reactivation from latency.  To further pursue the development of antivirals targeting viral 
transcription, mifepristone analogs were analyzed to determine cytotoxicity, inhibition of 
transactivation, and inhibition of viral replication.  Results exemplified that while mifepristone 
analogs were able to inhibit both transactivation and replication, none of the chosen analogs were 
able to work in a more effective manner than mifepristone. Taken together, mifepristone 
demonstrates characteristics complementary to the development of this compound as a new 
antiviral, in conjunction with the current HAART regimen. 
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6. CHAPTER SIX:  DISCUSSION 
 
There exists an obvious and urgent need to find the elusive “cure” for HIV/AIDS, whether it be 
by vaccine, antiviral, or microbicide.  Frustrations have been mounting in the scientific and 
political communities over the lack of such a cure, even after now over twenty years of HIV 
research and funding.  The phenomenon of HAART, prolonging the lives of possible millions 
and preventing the spread of this virus, was and is an amazing and currently evolving 
achievement.  The problem arises, however, with the fact that HAART is not the “cure” that so 
many are searching for; instead it is a way to prolong the life of those infected.  Unfortunately, 
the inability to follow the toxic and strict drug regimen that is HAART, combined with the 
evolution of HIV leading to drug-resistant strains as well as viral reservoirs, leads to an often 
similar outcome: the eventual succumbing of the patient to the viral parasite that ultimately leads 
to death.   
 
The relatively small virus that is HIV is composed of only nine proteins, functioning in 
structural, enzymatic, and accessory roles.  HAART focuses on only a few of these proteins:  the 
envelope, reverse transcriptase and protease, along with targeting nucleotide/nucleoside addition 
involved with basic replication.  While vaccine studies currently involve few genes found within 
the viral genome, as of yet there have been no vaccines that have fully protected human subjects, 
though studies in non-human primates have demonstrated otherwise (86-90).    
 
The 96-amino acid HIV-1 accessory protein Viral Protein R (Vpr) is evolutionarily conserved 
within the various species of virus, including HIV-1, HIV-2 and SIV (40).  Further studies into 
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 the relevance of this protein, however, have demonstrated that Vpr is active in several different 
pathways and serves a variety of functions including locating the pre-integration complex, G2/M 
cell cycle arrest, apoptosis, evasion strategies, regulation of cellular immune function, and 
increasing transactivation (29-39).   
 
The focus of this thesis is two-fold:  First, to identify the role of Vpr in viral transactivation and 
secondly, to determine a way of inhibiting this transactivation.  Vpr is present in the virion prior 
to the production or presence of Tat, therefore Vpr may help transactivate initial viral genes. Vpr 
has also been shown as necessary for the  optimal infection of non-dividing cells such as 
macrophages. Macrophages are initial targets of the virus, specifically in the mucosa in both 
vertical and horizontal transmission (25).  Taken together, the presence of Vpr in the virion as 
well as the necessity of Vpr to infect initial targets such as macrophages, enables one to both 
investigate the mechanism(s) underlying Vpr-mediated transactivation as well as view this 
protein as a possible target for antiviral therapy.   
 
Initial studies were performed in order to demonstrate an increased transactivation of the 
autologous promoter HIV-1 LTR in the presence of Vpr.  By exampling an increase in 
transactivation directly correlating with an increase in the concentration of Vpr, or put more 
simply, a dose-dependent increase in transactivation in the presence of Vpr, this strong example 
was demonstrative of the role of Vpr in HIV-1 LTR-driven transactivation (Figure 11).  The 
question subsequently and obviously became then how exactly was Vpr able to increase 
transactivation?   
 
74 
 Previous work from our group determined that the GRE sequences present within the HIV-1 
LTR is the region specifically influenced by the presence of Vpr (49,75).  To further this 
investigation, a series of reporter assays were constructed utilizing the reporter construct GRE-
luciferase in the presence of Vpr in the CV-1 cell line, chosen for its lack of endogenous GR 
(Figure 13 ).  Results demonstrated that Vpr was specifically influencing the promoter response 
element GRE by increasing transactivation in a dose-dependent manner, further confirming our 
published reports (49).     
 
Vpr, comprised of three helices each containing the motif LxxLL, is known to interact with a 
variety of proteins, supporting studies that implicate the LxxLL motif in protein-protein 
interactions (47,48).  Transcription factors are also known to interact with this LxxLL motif.  
The knowledge that Vpr was able to increase the transactivation of GRE-driven genes as 
determined by reporter assay, combined with studies on transcription factors implementing their 
interaction with LxxLL motifs, supported the theory that the transcription factor interacting with 
the GRE promoter region, the Glucocorticoid Receptor (GR), could be the key factor to the 
increased transactivation.  Protein-interaction studies where therefore completed, showing a 
direct interaction between Vpr and GR (49).  Further studies also demonstrated that Vpr 
increased the binding of GR to its response element, GRE, in a similar manner to that of 
dexamethasone (49).  
 
It was of the utmost importance to determine the appropriate concentrations of DNA to add to 
luciferase reporter assay transfections.  As seen in Figure 12, each cell line necessitated a 
different concentration of Vpr to achieve optimal transactivation.  Results showed that the 
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 highest amount of Vpr-mediated transactivation occurred when using 0.5µg pVpr in HeLa and 
0.25µg in CV-1 cells, whereas 2.5µg of pVpr was needed to observe optimal transactivation in 
HEK293 cells.  These studies were conducted using both autologous and heterologous promoters 
in HeLa, CV-1, and HEK293 cells, with similar results independent of promoter used. 
Interestingly, in comparing both GRE- and HIV-1 LTR-promoted transactivation, the HIV-1 
LTR promoter activation gave a much higher luciferase reading than that of GRE.  This could be 
due to the fact that GRE promoter activation is dependent mainly on the presence of GR whereas 
the HIV-1 LTR promoter contains various binding areas for a number of different transcription 
factors.  Therefore, the HIV-1 promoter will ultimately have a much higher transactivation of 
downstream genes than that of GRE alone, as there are many more factors that are able to 
activate the promoter region in an additive manner.  
 
After establishing that Vpr increased transactivation through an interaction with the cellular GR, 
leading to the increased transcription of GRE- ,or subsequently HIV-1 LTR-, driven genes, the 
next aim of this thesis became finding out how to disrupt this increase in transcription.  Because 
Vpr-mediated viral transactivation occurred in the presence of GR, the GR antagonist 
mifepristone was investigated, to determine if this compound could intervene with the Vpr-GR 
interaction, leading to a decrease in viral transcription. Mifepristone has been well-studied, at 
least in the context of short-term use, and is currently being researched for a variety of reasons 
including having anti-cancer properties, for neuroprotection, and for the treatment of 
Alzheimer’s disease (91-93).   When applied to reporter transactivation models, mifepristone was 
able to decrease Vpr-mediated transactivation by greater than 90% in different cell lines (HeLa,  
and HEK293; Figure 16).  As the mifepristone-induced inhibition of transactivation was dose-
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 dependent, it was therefore concluded that the effects of this GR antagonist were able to 
decrease, almost completely, the effects of Vpr-mediated transactivation. 
 
Dexamethasone is the researcher’s cortisol for in vitro studies, as it acts in a similar manner to 
cortisol and other steroids in the presence of hormone receptors such as GR.  While initial results 
complemented by theory demonstrated that Vpr was able to work in a manner similar to that of 
dexamethasone, it was important to determine how effective both ligands were in mediating 
transactivation.  As was concluded, Vpr did work in a manner of effectiveness similar to 
dexamethasone.  And most interesting was the fact that when both Vpr and dexamethasone were 
added together, rather than acting as ligand competitors, Vpr and dexamethasone worked in an 
additive manner, leading to an eventual saturation, if you will, of transactivation (Figures 18 and 
19).  The inhibitory effects of mifepristone on promoter-driven transactivation were further 
exemplified when even in the presence of both dexamethasone and Vpr, a dose-dependent 
inhibition of transactivation was still demonstrated in the presence of the GR antagonist.    
 
Initial results from the transactivation models gave rise to the further investigation into 
mifepristone as a possible antiviral compound.  The fact that mifepristone demonstrated 
relatively low toxicity in both MTT and trypan blue exclusion assays allowed the continuation of 
the conducting of antiviral assays.  To investigate the ability of mifepristone to inhibit HIV-1 
infection, wild-type infectivity assays were developed  In order to assess the efficacy of 
mifepristone in the context of wild-type infection, the T-cell line, CEMx174, was infected with 
an MOI of 0.5 of the EGFP-expressing virus, NL4-3-EGFPwt.  This NL4-3 wild-type virus 
expresses the EGFP protein, in which infected cells can be analyzed by fluorescent microscopy 
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 as well as FACS analysis.  Mifepristone was added post-infection to the CEM cells and samples 
were taken 24 hours after a second dose of mifepristone on day three.  FACS analysis and p24 
analysis revealed that mifepristone was able to inhibit viral replication in a dose-dependent 
manner, even at low concentrations of the compound (0.5µM) (Figures 22 and 23).     
 
To further determine the effects of mifepristone on the inhibition of infection, it was determined 
to next investigate the effects of this compound on virus-infected PBMCs.  The use of PBMCs 
demonstrates a relevant system in which to test mifepristone, as these cells include varying 
populations of initial viral targets, including both CD4-expressing T cells as well as monocytes.  
To conduct these assays, initial trials were conducted to determine the appropriate MOI in which 
to infect the donor PBMCs. After comparing p24 to MOI, it was determined that the only 
accurate way to infect cells was to determine the number of infectious particles per mL of each 
virus rather than p24, as comparative studies between p24 and MOI demonstrated that the 
number of infectious particles could change dramatically within different stocks of virus, even if 
the p24 was equivalent.  In several different donors, cells were infected with various MOIs of 
virus, to see which would be most appropriate for this compound.  If the viral titer was too high, 
infection overcame the cells immediately, with no chance of mifepristone, AZT, or analogs 
working appropriately.  If the MOI was too low, there was little to no infection, which would 
obviously not prove either way if mifepristone was or was not able to inhibit virus replication.  
Each donor was different, however; some would infect at a much higher rate than others, and 
others would not infect at all even after the correct MOI was determined and used.  Such are the 
trials of research.  
 
78 
 After the appropriate MOI was established, PBMCs were infected with the dual-tropic 89.6 
virus, as this virus is able to infect both R5 and X4 receptor-expressing cells including both 
initial target populations, T-cells and monocytes.  Mifepristone was added post-infection in a 
dose-dependent manner to the PBMCs and supernatant samples were analyzed for the presence 
of p24, indicative of viral replication.  Results demonstrated that mifepristone was able to inhibit 
the viral replication within these cells in a dose-dependent manner, exemplifying the efficacy of 
this compound.    
 
To take this PBMC infection antiviral one step further, the patient isolate H112 was used to 
infect PBMCs at an MOI of 0.1.  Post-infection, mifepristone was administered in a dose-
dependent manner and supernatant samples were taken every three days and analyzed for p24.  
Results demonstrated that mifepristone was able to inhibit viral replication in a dose-dependent 
manner.  Though the treatment with mifepristone did not inhibit replication when the lower 
concentrations were used, this compound was still effective at inhibiting viral replication when 
the higher concentrations were administered.  This demonstrates that mifepristone was still able 
to combat patient isolates in a similar manner to the often-used lab isolate 89.6.   
 
Vpr has an integral role in the infection of macrophages.  In order to assess the effects of 
mifepristone on macrophage infection, macrophages were infected with the macrophage-tropic 
viral strain, Ba-L at an MOI of 0.1.  Post-infection, mifepristone was added in a dose-dependent 
manner and similar to the PBMC antivirals, supernatant was collected every two or three days 
and p24 concentration was determined by ELISA.  Again, mifepristone was able to inhibit viral 
replication in a dose-dependent manner as seen in several different donors.  These experiments 
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 were useful in determining the efficacy of mifepristone when used specifically for not only an 
initial cellular target of HIV-1, but one in which Vpr plays a major role in allowing viral 
infection. 
 
Mifepristone inhibits the transactivation of viral genes, based on its interference with the 
mechanism of promoter activation.  In order to determine if there was a difference in the efficacy 
of mifepristone dependent on when it was administered in comparison to when supernatant 
samples were taken, several trials were conducted by altering not only the time mifepristone was 
added (every two days versus every three days), but also by altering the time samples were taken 
(24 hours post-compound addition versus 48 hours post-compound addition).  Results concluded 
that there was no significant difference when any of the parameters were altered as to the amount 
of inhibition that was demonstrated in the presence of mifepristone.  
 
 
The possibility of mifepristone as an antiviral in its ability to decrease transactivation was 
demonstrated in these experiments.  However, in order to determine if structural analogs of 
mifepristone exhibited less toxicity or greater efficacy at inhibiting virus, mifepristone analogs 
were assessed to determine the effects of compounds on both viral promoter transactivation as 
well as viral replication.  Several compounds were acquired from NCI: mifepristone analogs 
92336, 641295, and 666510. These compounds were analyzed in the context of both inhibition of 
viral transactivation as well as inhibition of viral replication. Toxicity results of these compounds 
were very similar to those of mifepristone, though they were slightly more toxic to macrophages.  
Though transactivation models demonstrated a dose-dependent decrease in Vpr-mediated 
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 transactivation and antiviral models demonstrated similar inhibition, mifepristone was able to 
work in a more effective manner than any of these compounds.  Therefore, it was concluded that 
these mifepristone analogs, while inhibiting the transactivation of viral genes, were not as 
effective as mifepristone. 
 
Since mifepristone specifically targets Vpr-mediated transactivation in the presence of GR, 
initial aspirations on the purpose of mifepristone were as a microbicide.  In order to determine 
the effects of mifepristone on a pre- versus post-treatment regimen, cells or virus were pre-
treated with the compound prior to infection and were compared to cells or virus treated post-
infection.  Results demonstrated that there was no significant difference in the effects of 
mifepristone on PBMCs or macrophages.  
 
One of the major dilemmas in combating HIV-1 infection is the presence of viral reservoirs.  As 
Vpr is present in the virion prior to the production of Tat, initial transactivation of HIV-1 LTR-
driven genes may in fact not only jumpstart viral transcription, but may re-activate latent virus 
hidden in these reservoirs.  Vpr has already been shown to re-activate latent virus (84, 85). To 
assess the efficacy of mifepristone in preventing the reactivation of viral production from 
reservoirs, U1/HIV-1 cells were activated by TNF-α as well as by AT-2 –inactivated NL4-3 in 
the presence of a dose-dependent regimen of mifepristone. TNF-alpha was used as it is one of 
the major cytokines which regulates viral transcription mediated by the HIV-1 LTR through the 
NF-ĸB transcription factor.  AT-2 -inactivated virus particle-triggered reactivation is due solely 
to the proteins present within the virion, one of which is Vpr.  Tat is not present as the virus is 
non-functional and Tat is a late expressing protein.  Therefore, we are able to implicate Vpr as a 
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 transactivating factor leading to the re-activation of latent virus.   After four days, samples were 
taken for p24 analysis.  Results demonstrated that mifepristone was able to prevent the re-
activation of viral production from latency in a dose-dependent manner, not only in the presence 
of cytokine-induced re-activation, but also by viral protein-induced reactivation.   These initial 
studies demonstrated the effectiveness of mifepristone in combating viral reservoirs, and 
possibly allowing the prevention of reactivation from latency.   
 
Taken together, Vpr was able to mediate transactivation by acting as ligand and utilizing the 
Glucocorticoid Receptor pathway.  The GR antagonist, mifepristone, inhibited Vpr-mediated 
transactivation of both autologous (GRE) and heterologous (LTR) promoter-driven genes in a 
dose-dependent manner.  Mifepristone was also able to inhibit wild-type and viral
isolate infection in primary cells in a dose-dependent manner.  Finally, this compound effectively 
decreased the re-activation of latent viral reservoirs in a dose-dependent manner.  Therefore, we 
conclude that mifepristone could possibly compose a new class of antivirals, targeting the 
accessory protein Vpr and preventing transcription of viral genes, both in active infection as well 
as viral reservoirs.  While mifepristone alone would be unable to fully combat infection, this 
compound could be used in conjunction with current HAART regimens to not only prevent viral 
transcription, but also combat viral reservoirs, preventing the reactivation from latency. 
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7. FUTURE DIRECTIONS 
 
Initial studies on the antiviral effects of mifepristone include the mechanism behind Vpr-induced 
transactivation and the effects of mifepristone on the transactivation of autologous and 
heterologous promoters, the inhibition of viral replication in wild-type infectivity assays,  and 
the inhibition of viral reactivation from latency.   To further these studies: 
 
1) A more detailed determination of the interaction between Vpr and GR should be conducted 
based on GR mutant studies including reporter transactivation assays, protein-protein interaction 
studies, and immunofluorescence to determine co-localization of GR and Vpr within the cell.  In 
this way, the location of the interaction between Vpr and GR within the GR protein could be 
established, and possible other antivirals preventing this interaction could be investigated.   
 
2) An animal model such as rhesus macaques could be investigated in order to determine the 
effects of mifepristone using SHIV.  Mifepristone could be given in pre- versus post-treatment 
both as a microbicide as well as orally in order to determine if this compound can prevent viral 
replication. 
 
3)  The effects of mifepristone on latent viral reservoirs could be more fully established.  For 
example, rather than using U1/HIV-1 cell lines, macrophages could be infected and brought to 
latency.  Re-activation could be induced in the presence of mifepristone and the effects of this 
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 compound could be determined.  Also, resting T-cell reservoirs could be investigated as well as 
macrophage reservoirs. 
 
4)  The effects of mifepristone on pregnancy.  Because mifepristone has abortive properties, 
pregnant women should not take this compound as an antiviral.  Further studies need to be 
conducted to determine the effects of mifepristone on late stages of pregnancy. 
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